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Biosurfactants (BSs) comprise a wide range of structurally different organic 
compounds produced by numerous prokaryotic and eukaryotic microorganisms. 
These molecules, generally localized on microbial cell surfaces or excreted 
extracellularly, are characterized by the presence of both hydrophilic and 
hydrophobic moieties within the same structure with allow them to exhibit surface 
activities [1]. Even if, in literature the terms ‘biosurfactants’ and ‘bioemulsifiers’ 
are often used interchangeably, molecules that reduce surface and interfacial 
tension at gas-liquid-solid interfaces are indicated as biosurfactants while those that 
are able to reduce the interfacial tension between immiscible liquids or at the solid-
liquid interfaces forming stable emulsion are called bioemulsifiers [2].  
The hydrophobic moiety of these compounds aggregates at the surface that 
represents the hydrophobic phase while the hydrophilic moiety is oriented towards 
the solution or hydrophilic phase. These structural orientation on the surfaces and 
interfases confers to these compounds a range of properties, such as the ability to 
lower surface and interfacial tension of liquids and the formation of micelles and 
microemulsions between different phases [3,4]. In heterogeneous systems, they 
tend to aggregate at the phase boundaries or interfaces, and form a molecular 
interfacial film that affects the properties of the original surface.  
In the last twenty years a large amount of research activity has been dedicated to 
biosurfactants as potential replacement for synthetic surfactants in many 
environmental and industrial applications such as bioremediation, enhanced oil 
recovery, paint, textile, detergent, cosmetic, food, agrochemical fields and several 
commercial products have already been issued [5].  
More recently, numerous investigations have lead to the discovery of many 
interesting chemical and biological properties of biosurfactants and several 
pharmaceutical and medical applications have been envisaged [1,2,6]. In particular, 
their ability to destabilize membranes by disturbing their integrity and permeability 
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leading to metabolite leakage and cell lysis [7-11], as well as their propensity to 
partition at the interfaces, modifying surface properties and thus affecting 
microorganisms adhesion, are important functions for antimicrobial and antibiofilm 
applications. Furthermore, some experimental results suggest that they are non-




BSs are mainly classified according to their chemical composition, molecular 
weight, and mode of action. They are divided into two groups: low molecular 
weight molecules (biosurfactants) that efficiently reduce surface and interfacial 
tension and high molecular weight polymers (bioemulsifiers) that stabilize 
emulsion without lower the surface tension [15,16]. Their hydrophobic moiety may 
be composed of an acid, peptide cations, or anions, mono-, di- or polysaccharides, 
and the hydrophobic moiety may include unsaturated or saturated hydrocarbon 
chains or fatty acids [1].  
The best studied biosurfactants are lipopeptides such as surfactin and fengicin. 




Lipopeptides are small molecules that are formed by cyclic or short linear 
peptides linked with a lipid tail or other lipophilic molecules [17,18]. There are 
different families and each family is constituted of several variants, which can 
differ in their fatty acid chain and their peptide moiety [19-22]. Lipopeptides are 
synthesized by many species of Bacillus and other species such as Actinoplanes, 
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Lyngbya, Pseudomonas, Streptomyces, Tolypothrix and in the fungi Aspergillus 
nidulans [23]. A large collection of these molecules (polymyxins, polypeptins, and 
octapeptins) can be classified as cyclic cationic lipopeptides. These molecules are 
cyclized at the C-terminus by an ester or amide bond and the lipid tail is 
incorporated through acylation of the N-terminal amino acid. The overall cationic 
charge derives from the incorporation of multiple residues of the non-proteogenic 
amino acid 2,4-diaminobutyric acid. Cyclic non-cationic lipopeptides include 
iturin, surfactin and fengycin. Surfactins (A, B and C) consist in a loop of seven 
amino acids, with the chiral sequence LLDLLDL, linked to a β-hydroxy fatty acid 
chain via a lactone bond [24]. At position 7, surfactin A presents L-Leu, surfactin B 
presents L-Val and surfactin C presents L-Ile [25]. Furthermore, surfactin is a 
mixture of isoforms characterized by a different acyl chain length (C13-C15) which 
confers selective properties to the biosurfactant [26,27]. Iturins (iturin A, C, AL, 
mycosubtilin, bacillomycin L, D, F and Lc) are heptapeptides with the chiral 
sequence LDDLLDL and are cyclized by an amide bond between the N-terminal β-
amino fatty acid and the C-terminus. Furthermore, acyl chain length range from 14 
to 17 C atoms, resulting in a mixture of isomers. Fengycin is a mixture of two 
homologues differing for their amino acid sequence. Its structure consists of a β-
hydroxy fatty acid linked to the N-terminus of a decapeptide, including four D-
amino acids residues and the rare amino acid ornithine. The C-terminal residue of 
the peptide moiety is linked to the tyrosine residue at position 3, forming the 
branching point of the acyl peptide and the eight-membered cyclic lactone. The 
chiral sequence is LDDDLDLLLL. Fengycin A and B present at position 6 the 
amino acid D-Ala and D-Val respectively. A series of isoforms is present in 
fengycin family by varying the length of β-hydroxy fatty acid tail, linked at 
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2.2. Glicolipids  
Glycolipids are commonly mono disaccharides molecules in combination with 
long chain aliphatic acids or hydroxyaliphatic acids. Rhamnolipids, mainly 
produced by Pseudomonas and Burkholderia genus, consist of one or two 
rhamnose sugar moieties linked to one or two β-hydroxy fatty acid chains [28]. 
Investigations have revealed a large diversity of congeners and homologs produced 
by this strain following different culture conditions and by other bacterial species 
[29].  
 
Figure 1. Chemical structures of the main low molecular weight microbial surface 
active compounds [2]. 
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Trehalolipids production is associated with most species of Mycobacterium, 
Rhodococcus and Corynebacterium [30]. These molecules are composed by a 
trehalose, linked by an ester bond to a-branched b-hydroxy fatty acids [31]. The 
most reported trehalose lipid is trehalose 6,6’-dimycolate, which is a α -branched 
chain mycolic acid esterified to the C6 position of each glucose [31]. Sophorolipids 
are most commonly produced by Candida bombicola and Candida apicola, along 
with Rhodotorula bogoriensi, Wicherhamiella domercqiae, Pichia anomala 
[32,33]. They can be classified in two major groups: the acidic sophorolipids 
comprising of a disaccharide, sophorose, linked to the sub-terminal or terminal 
carbon of the fatty acid chain and the lactonic sophorolipids where the carboxylic 
acid portion of the fatty acid is joined to carbon 4’’ of the disaccharide unit [34]. 
Mannosylerythritol lipids (MELs) are generally produced by Pseudozyma yeasts 
species, P. rugulosa, P. aphidis and P. Antarctica [35]. These molecules contain a 
4-O-b-D-mannopyranosyl-D-erythritol connected to two medium length chains of 
fatty acyl esters [36]. Based on the degree of acetylation MELs have been classified 
as MEL-A when diacetylated, MEL-B and MEL-C when monoacetylated and 
MEL-D when no acetylated [37].  
 
3. Biosurfactants as biological control agents 
The urgent need for new antimicrobial compounds remains a major concern 
nowadays because of the newly emerged pathogens and conventional others which 
have become almost insensitive to existing antibiotics [38,39]. Microbial 
metabolites are recognized as a major source of compounds endowed with potent 
biological activities and, among these, some biosurfactants have been described as 
alternatives to synthetic medicines and antimicrobial agents [6,40,41]. Moreover, 
thanks to their ability to modulate the interaction of cells with surfaces, 
biosurfactants are able to interfere with microbial adhesion and biofilm formation, 
an important and mostly hazardous occurrence on medical devices, especially as 
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bacteria within such biofilms usually become highly resistant to antibiotics and 
adverse environmental challenges [42,43]. From this point of view, it could be 
useful to increase the efficacy of known antibiotics and biocides with alternative 
strategies aimed at decreasing bacterial adhesion and reducing the biofilm 
populations on medical device surfaces. 
 
3.1. Mechanisms of action 
Understanding the functional mechanisms of biosurfactants is of great help for 
the disclosure of interesting applications. Among biosurfactants, lipopeptides and 
glicolipids have the most potent antimicrobial activity and represent an important 
source for the identification of new antibiotics. 
The antimicrobial activity of lipopeptides is due to their ability to self-associate 
and form a pore-bearing channel or micellular aggregate inside a lipid membrane 
[44,45]. Thanks to these properties, lipopeptides usually cause membrane 
disruption, increased membrane permeability, metabolite leakage and cell lysis. 
Furthermore, changes in membrane structure or disruption of protein 
conformations alter important membrane functions such as transport and energy 
generation [23,46]. It has been observed that pore formation in membranes occurs 
after lipopeptide oligomer binding, some of which are Ca
2+
 dependent multimers 





leading to membrane disruption and cell death [47-49]. The bactericidal activity of 
lipopeptides increases with the presence of a lipid tail length of 10-12 carbons 
atoms whereas an enhanced antifungal activity is exhibited in lipopeptides with a 
lipid tail length of 14 or 16 carbon atoms [23]. In addition, due to the difficulty of 
the target cells to reorganize their membranes, the development of resistant strains 
is extremely reduced [48].  
Surfactin, known as one of the most powerful biosurfactants, destabilize 
membranes disturbing their integrity and permeability [50]. Infact, surfactin creates 
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changes in physical membrane structure or disrupts protein conformations which 
alter important membrane functions such as transport and energy generation [7-
11,51,52]. A key step for membrane destabilization and leakage is the dimerization 
of surfactin into the bilayer [44]. In vitro, the incorporation of surfactin into the 
membrane gives rise to dehydration of the phospholipid polar head groups and the 
perturbation of lipid packing which strongly compromise the bilayer stability, 
leading to the disturbance of the membrane barrier properties [44]. The degree of 
phospholipid bilayer perturbation depends on the concentration of surfactin. At low 
concentrations surfactin penetrates into the cell membrane, where it is completely 
miscible with the phospholipids and forms mixed micelles. At moderate 
concentrations this lipopeptide creates domains segregated within the phospholipid 
bilayer that may contribute to the formation ion-conducting pores in the cell 
membrane; at high concentrations, surfactin operates as a detergent, leading to 
membrane disruption and permeabilization [53,54].  
Mechanisms of action and activity of other lipopeptides have been reviewed by 
Cochrane and Vederas [55]. Polymyxins primarily exert their strong bactericidal 
effect against Gram-negative bacteria through the binding of the lipid A component 
of lipopolysaccharide (LPS) and disruption of the outer membrane, followed by 
permeabilization and disruption of the inner membrane [56,57]. Octapeptins A and 
B display broad-spectrum activity against both Gram-positive and Gram-negative 
bacteria and have also antimicrobial activity against some filamentous fungi, 
protozoa and yeasts due to their ability to disrupt the cytoplasmic membrane 
[58,59]. The iturin family exerts fungicidal action through the interaction with 
sterol components in the fungal membrane, leading to an increase in K
+
 
permeability [60,61]. Concerning the fengycin family, even if the complete mode 
of action is not known, current studies suggest it operates through a membrane 
disruption mechanism [45,62,63]. 
Concerning glycolipids mode of action, Sotirova et al. [64] demonstrated that 
the exposure of P. aeruginosa to rhamnolipids causes a multi-component response 
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of the bacterial cells characterized by a reduction of total cellular LPS content, an 
increase in cell hydrophobicity and changes in membrane proteins and surface 
morphology. At the same manner, the antimicrobial activity of sophorolipids 
involves mechanisms that cause destabilization and alteration of the permeability of 
the cellular membrane [65]. Furthermore, Ortiz et al. [7,8] have recently studied the 
interactions of bacterial biosurfactants trehalose lipids with phosphatidylserine and 
phosphatidylethanolamine membranes. The results demonstrated that trehalose 
lipids, when incorporated into the bilayers, increased hydrocarbon chain 
conformational disorder and decreased the hydration of the interfacial region of the 
bilayer, leading to structural perturbations that might affect the function of the 
membranes. 
The ability to reduce microbial cells adhesion to surfaces, thus limiting biofilm 
formation, is another well-known property of biosurfactants. The initial deposition 
rates and numbers of microorganisms adhering to a surface are determined by a 
complex interplay of hydrophobicity (interfacial free energies), electrostatic 
interactions, the presence of specific receptor sites on the microbial cell surfaces 
and possible biosurfactants produced [66]. In particular, biofilm formation on solid 
surfaces is generally directly proportional to the hydrophobicity of the surface, as 
long as the suspended medium is a simple buffer [67]. Microbial adhesion on 
hydrophobic substrates (e.g. silicone rubber) is presumably related to the removal 
of interfacial water between microorganism and surface interacting surfaces, which 
facilitates close approach [67]. These Authors suggested that biosurfactants reduce 
hydrophobic interactions, resulting in a decrease in the hydrophobicity of the 
surface, which interferes with the microbial adhesion to the surface and 
consequently, alters biofilm development. 
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3.2. Antibacterial and antifungal activity of biosurfactants 
Lipopeptides form the most commonly reported class of biosurfactants with 
antimicrobial activity. Antimicrobial lipopeptides are surfactin, fengycin, iturin, 
bacillomycins and mycosubtilins produced by B. subtilis, lichenysin, pumilacidin 
and polymyxin B produced by B. licheniformis, Bacillus pumilus and Bacillus 
polymyxa, respectively, and cyclic lipopeptides such as daptomycin, from 
Streptomyces roseosporus and viscosin, from Pseudomonas [55]. Glycolipids, as 
well, have been reported to exhibit antimicrobial activities, in particular, 
rhamnolipids from P. aeruginosa, sophorolipids from C. bombicola, 
mannosylerythritol lipids (MEL-A and MEL-B) from Candida antarctica [68]. 
Ghribi et al. [69] investigated the antimicrobial activity of a biosurfactant 
produced by the strain B. subtilis SPB1 against bacteria and fungi. The 
biosurfactant exhibited a broad spectrum of action, including antimicrobial activity 
against microorganisms with multidrug-resistant profiles. The compound showed 
higher activity against Gram-positive cocci than against Gram-negative bacilli and 
its activity was particularly significant against Enterococcus faecalis. Ding et al. 
[70] isolated two lipopeptide antibiotics, pelgipeptins C and D from the strain 
Paenibacillus elgii B69, active against a number of Gram-positive and Gram-
negative bacteria and against pathogenic fungus strains of Candida. In particular, 
pelgipeptin D exhibited rapid and effective bactericidal action against a methicillin 
resistant strain of S. aureus and, according to acute toxicity test, the intraperitoneal 
LD50 value of pelgipeptin D was slightly higher than that of the structurally related 
antimicrobial agent polymyxin B. Tabbene et al. [71] studied three anti-Candida 
albicans compounds derived from the strain Bacillus subtilis B38, designated a1, 
a2 and a3, and identified as analogues of bacillomycin D-like lipopeptides. The 
compound a3 displayed the strongest fungicidal activity and was even more active 
than amphotericin B against the pathogenic strain C. albicans sp. 311 isolated from 
finger nail. More recently, a lipopeptide produced by B. licheniformis M104 was 
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investigated as antimicrobial agent against Gram-positive bacteria (B subtilis, B. 
thuringiensis, B. cereus, Staphylococcus aureus, L. monocytogenes), Gram-
negative bacteria (P. aeruginosa, E. coli, S. typhimurium, P. vulgaris, K. 
pneumonia) and C. albicans [72]. All the tested microorganisms, with the 
exception of L. monocytogenes and K. pneumonia, were affected by the 
biosurfactant and S. aureus was the most susceptible. The antimicrobial effect the 
lipopeptide was time and concentration-dependent. The maximum inhibitory 
activity was observed at a concentration of 48 μg ml
-1
 after 12 h of treatment. The 
lipopeptide 6-2 produced by Bacillus amyloliquefaciens was found to have an 
interesting antifungal activity against Candida albicans, Metschnikowia 
bicuspidate, Candida tropicalis, Yarrowia lipolytica, and Saccharomyces 
cerevisiae [73]. The authors evaluated how lipopeptide 6-2 was able to kill C. 
albicans cells by scanning electronic microscope, revealing the presence of 
invaginations of the cell wall, the disruption of the whole cells and the 
disappearance of integrity of the cell wall. In addition, it was shown that the plasma 
membrane of the yeast cells was damaged by the treatment with lipopeptide 6-2 as 
well as the biosurfactant was responsible of the lysis of the C. albicans protoplast 
[73]. Very recently, Sharma et al. [74] purified and characterized a novel 
lipopeptide from Streptomyces amritsarensis sp. nov. The antimicrobial activity of 
biosurfactant was evaluated on a broad spectrum of bacteria and fungi. The MIC 
values of purified lipopeptide against B. subtilis (MTCC 619), S. epidermidis 
(MTCC 435), M. smegmatis (MTCC 6) and Methicillin Resistant Staphylococcus 
aureus (MRSA) were found to be 10, 15, 25 and 45 μg ml
-1
, respectively. No 
activity against any of the tested Gram-negative bacteria and against fungi was 
observed. The results concerning biosurfactant heat stability demonstrated that a 
treatment at 100 °C or 121 °C for 15 minutes reduced the antimicrobial action of 
13.7% and 18.2% respectively. In addition, the lipopeptide demonstrated to be non-
cytotoxic and non-mutagenic, which is an important prerequisite for the 
development of a drug. Liang et al. [75] analyzed the antimicrobial effect of a 
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biosurfactant obtained by cultivating the strain Paenibacillus macerans TKU029 in 
a medium with 2% (w/v) squid pen powder as carbon/nitrogen source. The purified 
TKU029 biosurfactant showed significant antimicrobial activity, which remained 
active after high-temperature treatment (121 °C) and at different pH (pH 4-10). 
TKU029 biosurfactant displayed a significant inhibitory effect on E. coli 
BCRC13086 and S. aureus BCRC10780 at concentrations of 2 and 1.5 mg m
-1
 
respectively. TKU029 BS also showed a good antifungal activity against F. 
oxysporum BCRC32121 and A. fumigatus BCRC30099. 
Samadi et al. [76] evaluated some biological activities of mono and di-
rhamnolipids produced by Pseudomonas aeruginosa MN1 isolated from oil 
contaminated soil. The mono-rhamnolipid containing fraction was a more potent 
antibacterial agent than the di-rhamnolipid fraction, in particular, against Gram-
positive bacteria that were inhibited at 25 μg ml
-1
 concentration. Moreover, the 
rhamnolipids remarkably enhanced the activity of oxacillin against Methicillin-
resistant Staphylococcus aureus strains and lowered the minimum inhibitory 
concentrations of oxacillin to the range of 3.12-6.25 μg ml
-1
. Abdel-Megeed et al 
[29] analysed the antimicrobial activity of a glycolipid produced by a strain of 
Rhodococcus erythropolis isolated from contaminated sites. It exhibited high 
inhibitory activity against Escherichia coli, Pseudomonas aeruginosa, Aspergillus 
niger and Aspergillus flavus. Investigation of the glycolipid effects by scanning 
electronic microscope, showed that bacteria were totally deformed and exhibited 
severe destruction. In other works Luna et al. [77] and Rufino et al. [78] 
demonstrated antimicrobial activity of two biosurfactants derived respectively from 
Candida sphaerica UCP0995 and Candida lipolytica UCP 0988 against Gram-
positive strains such as Streptococcus agalactiae, Streptococcus mutans, 
Streptococcus sanguis, Streptococcus oralis, Staphylococcus epidermidi and 
against Candida albicans. In the study conducted by Lotfabad et al. [79] the 
antibacterial ability of rhamnolipids produced produced by two P. aeruginosa 
strains, isolated from oil excavation areas in south of Iran, was elucidated. MR01 
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and MASH1 biosurfactants did not affect Gram-negative bacteria growth. On the 
other hand, they exhibited a strain dependent inhibitory effect against Gram-
positive bacteria. The MIC values of MR01 biosurfactant for S. epidermidis ATCC 
12228, B. cereus PTCC1247, E. faecalis ATCC 29212, and the clinical isolated E. 
faecalis were higher than the values obtained for MASH1 biosurfactant, whereas, 
MR01 biosurfactant presented lower MIC values for S. aureus ATCC 29213 and 
for the clinical isolated M. luteus in comparison to MASH1 biosurfactant. 
Rhamnolipids were also examined to evaluate their antimicrobial potential against 
L. monocytogenes and their combined effect with nisin against two wild-type 
isolates of L. monocytogenes with different susceptibility to these biosurfactants 
[80]. Rhamnolipids alone inhibited the 90.6% of the tested cultures and were 
characterized by MIC values ranging from 78.1 µg ml
-1
 to 2500 µg ml
-1
. The 
combination of nisin and rhamnolipids was bactericidal at lower concentration than 
for the individual antimicrobials, revealing a strong synergistic effect against L. 
monocytogenes isolates. Interestingly, Joshi-Navare and Prabhune [81] have paid 
attention to sophorolipids (SL) ad their synergistic effect with antibiotics. 
Tetracycline alone, at the concentration of 15 µg ml
-1
, was not able to totally kill S. 
aureus cells after 6 h of exposure but, when combined with sophorolipids (300 µg 
ml
-1
), a total inhibition of the strain was achieved after 4 hour and an increase of 
the inhibition of 22% in comparison to SL alone was observed after 2 hours of 
exposure. Similarly, Cefaclor achieved almost total inhibition of E. coli after 6 h 
exposure, SL alone was unable to completely inhibit bacterial growth, but when 
administered in combination, they resulted in faster killing of the bacterium. 
Scanning electron microscopy revealed that the cells treated with mixtures of SL 
and antibiotics were characterized by cell membrane damage and pore formation, 
leading to leakage of the cytoplasmic contents and accumulation of cell debris. A 
glycolipid biosurfactant from Halomonas sp BS4, containing 1, 2-Ethanediamine 
N, N, N’, N’- tetra and (Z)-9-octadecenamide, showed antibacterial activity against 
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S. aureus, K. pneumonia, S. pyrogenes and S. typhi and antifungal activity against 
Aspergillus niger, Fusarium sp, Aspergillus flavus and T. rubrum [82]. 
 
3.3. Biosurfactants as anti-adhesives and role in biofilms 
The continuous increase in the use of medical devices is associated with a 
significant risk of infectious complications, including systemic infections, septic 
thrombophlebitis, endocarditis, metastatic infections and sepsis. These microbial 
infections are due to the formation of biofilms, complex biological structures 
adhering to the medical device consisting of a sessile and multicellular community 
encapsulated in a hydrated matrix of polysaccharides and proteins. Once a mature 
biofilm is developed, the bacteria growing in the biofilm become highly resistant to 
both antimicrobial agents [83] and host immune response. The Gram-positive 
bacteria Staphylococcus epidermidis, S. aureus, Enteroccocus faecalis, constitute 
more than 50% of the species isolated from patients with medical device-associated 
infections. Candida spp., Pseudomonas aeruginosa and uropathogenic Escherichia 
coli are the remaining causal agents. Catheter-associated infections (CAIs), in 
particular, have become one of the most common sources of healthcare-associated 
infections [84,85]. Similarly, orthopaedic metallic prostheses are associated with a 
significant risk of infection [86,87]. 
Current biofilm preventive strategies are essentially aimed at coating medical 
surfaces with antimicrobial agents, a process not always successful [88]. Surface 
modification strategies based on plasma, UV and corona discharge treatment of 
typical catheter materials, such as silicone and polyurethanes, have been developed 
with the aim to increase material hydrophilicity, thus decreasing microbial 
adhesion and biofilm formation [89,90]. Such modifications have a temporary 
effect on silicone, due to the rapid rearrangement of macromolecular chains, 
leading to surface hydrophobicity recovery [91]. Surface coatings releasing 
biocides (e.g. nitric oxide, antibiotics or silver) have been developed on metallic 
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and polymer biomaterials, as short term antimicrobial strategies [92]. To obtain 
surfaces with permanent antimicrobial properties, polymeric and metal surfaces 
have been frequently modified via direct covalent coupling of antifouling (e.g. 
polyethylene glycole (PEG) [93]), cationic (e.g. polycarbonate copolymers [94], 
chitosan [95], quaternary ammonium salts [96] and cationic peptides [97]) or 
zwitterionic molecules (e.g. poly(sulfobetaine methacrylate) [98]). Main drawbacks 
of antimicrobial coatings arise from time limited effectiveness (as in the case of 
PEG-based coatings, which are susceptible to oxidative degradation [99]), 
development of microorganism resistance and potential toxicity towards human 
cells (as in the case of quaternary ammonium salts coatings [100]). 
In this context, biosurfactants have recently emerged as a potential new 
generation of antiadhesive agents with enhanced biocompatibility. Biosurfactants, 
have demonstrated the ability to interfere with biofilm formation, modulating 
microbial interaction with interfaces by altering the physical and chemical 
condition of the environment where biofilms are developing [101-107]. 
Rivardo et al. [108], observed that a lipopeptide biosurfactant produced by the 
strain B. subtilis V9T14 in association with antibiotics synergistically increased the 
efficacy of antibiotics against biofilm formation of the pathogenic E. coli CFT073 
and, in some combinations, led to the total eradication its biofilm. An international 
patent on this application has also been issued [109]; the biosurfactant composition 
can be used in combination with biocides, as an adjuvant, to aid in preventing 
formation and/or eradicating bacterial growth as planktonic cells or as a biofilm on 
biotic and abiotic surfaces. Janek et al. [110] investigated the role and applications 
of pseudofactin II, cyclic lipopeptide biosurfactant secreted by Pseudomonas 
fluorescens BD5, as an antiadhesive compound for medicinal and therapeutic 
applications. Pseudofactin II lowered the adhesion of Escherichia coli, 
Enterococcus faecalis, Enterococcus hirae, Staphylococcus epidermidis, Proteus 
mirabilis and Candida albicans to glass, polystyrene and silicone. In particular, 
pre-treatment of a polystyrene surface with 0.5 mg ml
-1
 pseudofactin II inhibited 
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bacterial adhesion by 36-90% and that of C. albicans by 92-99%. The same 
concentration of pseudofactin II dislodged 26-70% of pre-existing biofilms grown 
on previously untreated surfaces. Pseudofactin II also caused a marked inhibition of 
the initial adhesion of E. faecalis, E. coli, E. hirae and C. albicans strains to 
silicone urethral catheters. The highest concentration tested (0.5 mg ml
-1
) caused a 
total growth inhibition of S. epidermidis, partial (18-37%) inhibition of other 
bacteria and 8-9% inhibition of C. albicans growth. In other work, a lipopeptide 
biosurfactants from Paenibacillus polymyxa was able to inhibit single and mixed 
species biofilms [111]. This biosurfactant complex, mainly composed of fusaricidin 
B and polymyxin D1, reduced the biofilm biomass of Bacillus subtilis, 
Micrococcus luteus, Pseudomonas aeruginosa, Staphylococcus aureus and 
Streptococcus bovis, and inhibited a self-assembling marine biofilm in co-
incubation assays by 99.3% and disrupted the established marine biofilm thickness 
by 72.4%. Biofilm inhibition and antimicrobial activity of a lipopeptide 
biosurfactant produced by a soil strain of Bacillus cereus resistant to the heavy 
metals iron, lead and zinc was described by Sriram et al. [112]. It inhibited the 
biofilm formation in pathogenic strains of Pseudomonas aeruginosa and 
Staphylococcus aureus. The highest biofilm inhibition (57%) was observed against 
S. epidermidis at a concentration of 15 mg ml
-1
. In another work, marine bacterial 
culture supernatants of Bacillus pumilus and B. indicus significantly inhibited the 
initial attachment process and biofilm formation and dispersal of mature biofilms 
of Vibrio spp. strains [113]. The bacterial supernatants also reduced the surface 
hydrophobicity of Vibrio spp., which is one of the important requirements for 
biofilm development. Zeraik and Nitschke [114] assessed the effect of different 
temperatures on the anti-adhesive activity of surfactin and rhamnolipids 
biosurfactants on polystyrene surfaces, regarding the attachment of Staphylococcus 
aureus, Listeria monocytogenes, and Micrococcus luteus. Surfactin inhibited 
bacterial adhesion at all tested conditions, and its activity increased with the 
decrease in temperature, giving a 63-66% adhesion reduction in the bacterial strains 
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at 4 °C. Rhamnolipids promoted a slight decrease in the attachment of S. aureus 
but were not as effective. Prevention of Candida albicans biofilm formation on 
silicone disks and on acrylic resins for denture prostheses by lipopeptide 
biosurfactants produced by Bacillus sp. were reported by Cochis et al. [14]. 
Precoating with biosurfactants caused a greater reduction in biofilm cell number 
and viability than chlorhexidine. The antiadhesion activity of the biosurfactants 
was observed at low concentrations (78.12 μg ml
-1
 and 156.12 μg ml
-1
) which were 
noncytotoxic. In another work, the lipopeptide biosurfactant produced by Bacillus 
tequilensis CH (CHBS) was able to inhibit biofilm formation of pathogenic 
bacteria on both hydrophilic and hydrophobic surfaces [115]. E. coli and 
Streptococcus mutans biofilms were grown with different concentrations of 
biosurfactant on glass pieces or polyvinyl chloride surfaces. Biofilms of E. coli and 
S. mutans were observed on the surfaces co-incubated with 0 and 25 μg ml
-1
 
CHBS, whereas there was a complete absence of biofilm on the surfaces incubated 
with 50 and 75 μg ml
-1
 CHBS. Interestingly, CHBS did not inhibit the growth of E. 
coli and S. mutans planktonic cells under all tested concentrations, demonstrating 
that CHBS was not a bactericidal agent but only contrasted bacterial adhesion to 
different surfaces [115]. 
The anti-biofilm potential of a glycolipid surfactant produced by a tropical 
marine strain of Serratia marcescens was analyzed by Dusane et al. [116]. Pre-
coating of microtiter plate wells with the surfactants effectively reduced the 
development of Y. lipolytica biofilms. Moreover, rhamnolipid treatment disrupted 
pre-formed biofilms both in microtiter plates and on glass slides in a more effective 
manner than chemical surfactants. Confocal laser scanning microscopy confirmed 
the effective removal of biofilms from glass surfaces. 
Rhamnolipids and other plant biosurfactants have also recently been reported to 
have some role in the inhibition of complex biofilms and as adjuvants to enhance 
some antibiotics microbial inhibitors [43]. In another study, a glycolipid 
biosurfactant from Pseudomonas aeruginosa DSVP20 was evaluated for its ability 
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to disrupt C. albicans biofilm. The treatment with the di-rhamnolipid RL-2 at 
concentrations ranging from 0.04 to 5.0 mg ml
-1
 significantly reduced C. albicans 
adhesion on polystyrene surfaces (PS) in a dose-dependent manner. Data showed a 
reduction of the number of adherent cells, after 2 h of treatment, of about 50 % 
with 0.16 mg ml
-1
 RL-2, that gradually increased up to a completely inhibition of 
adherence at a concentration of 5 mg ml
-1
. Moreover, C. albicans biofilm on PS 
surface was disrupted up to 70 % and 90 % with RL-2 treatment at concentrations 
of 2.5 and 5.0 mg ml
-1
, respectively [117]. Very recently, Pradhan et al. [118] have 
studied a new glycolipid obtained from Lysinibacillus fusiformis S9. This 
biosurfactant showed a remarkable antibiofilm activity against pathogenic bacteria 
such as E. coli and S. mutans, without affecting microbial cell viability. In 
particular, the biosurfactant was able to completely contain the biofilms formation 
at a concentration of 40 μg ml
-1
. 
Anti-adhesive activities of two BSs named Rufisan and Lunasan, respectively 
produced by Candida lipolytica UCP0988 and Candida sphaerica UCP0995, 
against Gram-positive, Gram-negative and Candida albicans pathogenic bacteria 
were also described by Rufino et al. [78] and Luna et al. [77]. More recently, 
Padmapriya and Suganthi [119] have partially purified two biosurfactant produced 
by C. tropicalis and C. albicans and tested their anti-adhesive activity on different 
types of urinary and clinical pathogens. The results showed a reduction of adherent 
cells on the surface of urinary catheter pre-coated with biosurfactants and a higher 
activity of the biosurfactant synthesized by C. tropicalis in comparison with the 
biosurfactant synthesized by C. albicans. 
Anti-adhesive activity against two C. albicans pathogenic biofilm-producing 
strains was described by Fracchia et al. [120] with a biosurfactant produced by the 
strain Lactobacillus sp. CV8LAC, isolated from fresh cabbage. The biosurfactant 
significantly inhibited the adhesion of fungal pathogens to polystyrene of about 
80%. No inhibition of both C. albicans planktonic cells was observed, thus 
indicating that the biosurfactant displayed specific anti-biofilm formation but not 
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antimicrobial activity. The effect of the Lactobacillus acidophilus DSM 20079 
biosurfactant on adherence and on the expression level of the genes gtfB and gtfC 
in Streptococcus mutans biofilm cells were analyzed by Tahmourespour et al. 
[121]. The L. acidophilus biosurfactant was able to interfere with the adhesion and 
biofilm formation of S. mutans to glass slide and could also make streptococcal 
chains shorter. Moreover, several properties of S. mutans cells (surface properties, 
biofilm formation, adhesion ability and gene expression) were changed after 
treatment with L. acidophilus biosurfactant. Lactobacillus biosurfactants have also 
been patented as inhibitors of adherence and colonization of bacterial pathogens on 
medical devices, in particular for preventing urogenital infection in mammals 
[122]. The antiadhesive activity of a lipopeptide biosurfactant secreted by the 
probiotic strain Propionibacterium freudenreichii was analyzed by Hajfarajollah et 
al. [123]. The biosurfactant showed a significant anti-adhesive action against a 
wide range of pathogenic bacteria and fungi (E. coli. S. aureus, P. aeruginosa, B. 
cereus). The highest adhesion reduction was obtained for P. aeruginosa (67.1 %) at 
the concentration of 40 mg ml
-1
, whereas a lower activity was observed for S. 
aureus (32.3 %), B. cereus (39.1 %) and E. coli (47.7 %), at the same 
concentration. 
 
3.4. Industrial application in the pharmaceutical and biomedical 
fields 
In spite of the high number of publication describing the antimicrobial activity of 
biosurfactants and of patents addressed to their usage for health improvement, real 
applications in the biomedical and pharmaceutical industry remain quite limited 
[5]. Some lipopeptides have reached a commercial antibiotic status, like 
daptomycin [124], and the echinocandins caspofungin [125], micafungin [126] and 
anidulafungin [127]. Daptomycin (Cubicin®, Cubist Pharmaceuticals), a branched 
   Chapter 1 
19 
 
cyclic lipopeptide isolated from cultures of Streptomyces roseosporus [124], was 
approved in 2003 for the non-topical treatment of skin structure infections caused 
by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus 
(MRSA) and in 2006 for the treatment of bacteremia and endocarditis caused by S. 
aureus strains and MRSA. Daptomycin displays strong antibacterial activity 
against other important pathogens, such as vancomycin resistant Enterococci 
(VRE), glycopeptide-intermediate-susceptible S. aureus (GISA), coagulase-
negative Staphylococci (CNS), and penicillin-resistant Streptococcus pneumoniae 
[128]. The echinocandins caspofungin, micafungin and anidulafungin are low-toxic 
synthetically modified lipopeptides, originally derived from the fermentation broths 
of various fungi [129]. Echinocandins can inhibit fungal cell wall formation 
[130,131]. In particular, they show a fungicidal activity against most isolates of 
Candida spp., Aspergillus spp. and Pneumocystis carinii [132]. Caspofungin was 
the first licensed echinocandin, approved since 2001 for the treatment in adults - 
and since 2008 in pediatric patients - of oesophageal and invasive candidiasis, 
invasive aspergillosis in patients refractory or intolerant to standard therapy and for 
empirical therapy of suspected fungal infections in neutropenic patients [125]. 
Micafungin is used in immune compromised children to combat invasive fungal 
infections by Candida and Aspergillus species [126] whereas anidulafungin in the 
treatment of candidemia and other forms of candidiasis [127]. Lipopeptides with 
antimicrobial activity suitable for the treatment and prevention of microbial 
infections were also described in several preparations [133-137] showing potential 
for pharmaceutical applications. For example, the lipopeptides viscosin and 
analogues have been patented as therapeutic compounds that inhibit the growth of 
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4. Candida species medical device-associated infections 
Candida species are commensal fungi, belonging to the normal microbiota of 
mucosal oral cavity, gastrointestinal tract and vagina, that can be isolated from 
approximately 70% of the healthy population [139]. In healthy individuals their 
growth is localized by the action of immune system and the presence of other 
commensal microorganism. However, they can become opportunistic pathogens in 
critically ill or immunocompromised patients causing disabling and lethal 
infections [140,141]. 
Candida spp. are considered important pathogens due to their versatility and ability 
to survive in various anatomical sites. Their pathogenicity is associated with a 
number of virulence factor, the most important of which are the ability to evade 
host defenses, adhere to host tissue and medical devices, form biofilm, and product 
tissue-damaging hydrolytic enzymes [142]. Moreover, virulence includes host 
recognition, the production of degradative enzymes and the ability to transit from 
yeast to filamentous cells [143].  
Invasive candidiasis presents a high global mortality rate, ranging from 36% to 
63% in different patient groups [144,145], and is a significant problem in terms of 
patient management and healthcare costs in the public health system [146]. In 
particular, Candida albicans causes more than 50% of the cases of candidaemia in 
Europe [147]. Recent studies revealed that the majority of disease produced by 
Candida spp. is associated with biofilm formation [148]. Cells grow forming a 
multicellular community, both in tissues and on prostheses, catheters and other 
surfaces rather than living in their planktonic free form [149]. 
Transplantation procedures, the use of chronic indwelling devices, 
immunosuppression and prolonged intensive care unit stays are specific factor risks 
that contribute to increase the prevalence of these fungal diseases [150]. Candida 
spp. causes 10% of the overall infections of intravenous catheters and cardiac 
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devices prosthetic valves as well as 21% of the total cases of urinary catheters 
infection with a mortality rate of 20-40% [151].  
 
4.1. Central venous catheters 
The increased use of central venous catheters has been related to a steady rise of 
nosocomial bloodstream infections with significant increases in hospital costs, 
duration of hospitalization, and patient morbidity [152]. As shown by Scanning 
Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM), 
biofilms can be found on the outside or the inner lumen of virtually all central 
venous catheter [153]. Infections may arise at any time during hospitalization. 
Frequently, contamination occurs in the infusion fluid itself, or in the catheter hub, 
but, more often, organisms are introduced from the patient’s skin or from the hands 
of nursing staff. In some cases, the distal tip of the catheter is contaminated at the 
time of insertion but it is also possible that organisms can migrate down the 
catheter wound. Alternatively, Candida spp. can contaminate the catheter tip 
endogenously, if they are able to penetrate the intestinal mucosa and invade the 
bloodstream [154].  
Management of Candida catheter-related infections should include catheter 
removal plus treatment with antifungal therapy for at least 14 days after the last 
positive blood culture and when signs and symptoms of infection have resolved 
[155]. 
 
4.2. Urinary catheters 
Candida spp. are the microbial pathogens that are most frequently isolated from the  
urine samples of patients in surgical intensive care units (ICUs), with about 10–
15% of nosocomial urinary tract infections being caused by this yeast [156] 
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Candida infections of the urinary tract are strongly associated with the presence of 
a urinary catheter [151]. Catheterization can cause infection by introducing 
organisms during the catheterization process or by allowing migration of organisms 
into the bladder along the surface of the catheter from the external periurethral 
surfaces [155]. Distinction between Candida colonization of the urinary tract and 
infection is often problematic, and symptomatic candiduria occurs in a large 
proportion of catheterized ICU patients [156]. In these cases, candiduria, when 
treated, can be eradicated by antifungal therapy or catheter removal. Bladder 
irrigation with amphotericin B and oral fluconazole were equally efficient but 
recurrences were common with both approaches [151]. 
 
5. Candida albicans biofilm 
C. albicans is the fourth and third leading cause of hospital-acquired bloodstream 
and urinary tract infections, respectively [157] and represents the fungus most 
frequently associated with the formation of biofilms on a wide variety of medical 
devices [152,158-160]. 
Biofilms are structured microbial communities attached to a surface and 
surrounded by a self-produced extracellular, often slimy, matrix [161]. Cells in 
biofilm display altered phenotypes from those associated with planktonic 
counterpart. Biofilms help fungi to maintain their role as pathogen protecting cells 
from host defenses, withstanding competitive pressure from other organisms, and 
giving cells a markedly enhanced resistance to antimicrobial agents [162]. Drugs 
concentrations necessary for a 50% reduction of metabolic activity is 5-8 times 
higher in biofilms compared to planktonic cells, as well as minimum inhibitory 
concentrations (MICs) are increased 30- to 20,000-fold [163]. Consequently, 
biofilm related infections are extremely difficult, if not impossible, to eradicate, 
leading to surgical removal and later replacement of the infected device [164]. 
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In general, C. albicans biofilm formation in vitro consists of four stages: (1) 
adherence of yeast cells to a surface, (2) growth of the attached yeast cells into a 
thin layer of cells, (3) maturation of the biofilm with the development of 
pseudohyphae and hyphae, excretion of matrix material and (4) dispersal of yeast 
cells from the biofilm leading to colonization of other location within the host 
[150,165]. 
 
Figure 2. Stages of Candida albicans biofilm formation. Biofilm development 
can be viewed as a series of sequential steps: 1) the adherence phase, 2) the 
initiation phase, 3) the maturation phase and 4) the dispersal phase (modified from 
Finkel and Mitchell [166]) 
 
Candida biofilms formed in in vivo models seem to follow the same sequence 
[167]. However, maturation is faster and thickness is greater in these biofilms 
compared to those grown in in vitro systems. The thickness of a biofilm grown in 
vitro can range from 25 µm to 450 µm [150,168,169], whereas it usually exceeds 
100 µm in in vivo models [167]. 
The first factor that influences the fungal colonization of human tissues is the 
adhesion to host surfaces or biomaterials. This process is mediated by non-specific 
factors (hydrophobicity and electrostatic forces) and promoted by specific adhesins 
present on the surface of fungal cells that recognize and bind to amino acids and 
sugars on the surface of other cells or promote adherence to abiotic surfaces [170]. 
One of the most clearly defined biofilm adhesins that mediate surface binding is 
Eap1 [171]. This evidence is demonstrated by three observations: the expression of 
Eap1 in a non-adherent Saccharomyces cerevisiae strain confers adherence to 
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polystyrene; a C. albicans Eap1
–/–
 deletion mutant is defective in adherence to 
polystyrene; and a C. albicans Eap1
–/–
 deletion mutant is defective in biofilm 
formation, as assayed both in vitro and in an vivo catheter model [172]. The closely 
related cell wall proteins Als1 and Als3 also assume an important role in biofilm 
surface attachment [173]. It has been demonstrated that their expression in S. 
cerevisiae promotes binding to several different proteins [174] while their lacking 
give a C. albicans mutant defective in biofilm formation in vitro and in vivo 
(Nobile et al. 2008). Furthermore, catheter surfaces inoculated with a double 
mutant was found virtually devoid of cells after incubation in vivo [175]. Als1 
expression is detectable in cells grown as either yeast or hyphal cell types, whereas 
Als3 is expressed primarily or exclusively in hyphae. This finding suggest that the 
initial adherence step that leads to biofilm formation in vivo can be carried out by 
either yeast-form cells or hyphae [176]. 
The capacity of C. albicans to switch from yeast to hyphae is a crucial step in the 
formation of biofilms. Genetic analyses indicate that both yeast cells and hyphae 
are crucial for biofilm formation, which suggests that each cell type has a unique 
role in the process [166]. This morphological transition is induced by many 
environmental factors, such as serum, a temperature of 37°C, and neutral pH and 
repressed by the quorum sensing molecule E,E-farnesol [177]. Biofilm formation is 
prevented by this molecule, if provided during adherence, because it inhibits 
hyphal growth and the expression of necessary morphology-specific genes. In 
particular, farnesol inhibits the yeast-to-mycelium conversion of C. albicans [178]. 
The limited biofilms that form in the presence of farnesol comprise mainly yeast 
and pseudohyphal cells, rather than hyphae. Furthermore, farnesol also accumulates 
in supernatants of mature biofilms, where it stimulates the production of yeast cells 
and promotes biofilm dispersal [179]. 
The matrix is one of the most distinctive features of a microbial biofilm. It forms a 
three-dimensional, gel-like, highly hydrated and locally charged environment in 
which the micro-organisms are largely immobilized [180]. Matrix potentially 
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serves several special functions in the growing biofilm, such as defending against 
phagocytic cells, providing a scaffold to maintain biofilm integrity, limiting active 
drug diffusion, or a combination of all these. In C. albicans biofilms, matrix 
consists of carbohydrate, together with small amounts of proteins, hexosamine, 
phosphorus and uronic acid [181]. β-1,3 glucan is one of the main extracellular 
carbohydrate constituent and its increased production is associated with biofilm 
cells rather than planktonic counterparts. Furthermore, another important elements 
of matrix is represented by extracellular DNA. A recent study, reported that the 
detection of extracellular DNA through the addition of DNase to a mature biofilm 
partially disrupts the biofilm. At the contrary, the addition of extracellular DNA at 
the beginning of biofilm development results in mature biofilms with increased 
biofilm biomass, confirming that extracellular DNA in the matrix contributes to the 
structure and stability of a mature biofilm [179,181]. 
Mature C. albicans biofilms, mostly present after 24–48 h, have a highly 
heterogeneous architecture in terms of distribution of fungal cells and extracellular 
material. In addition, matrix-enclosed microcolonies are separated by water 
channels, which provide a mechanism for nutrient circulation within the biofilm 
[182]. Commonly, it is formed by a basal layer composed of several thicknesses 
cells in the yeast form adhering to the surface and, above this, a thick 
heterogeneous outer layer of filamentous cells in the hyphal form and a extensive 
exopolymeric matrix [183]. 
In the last phase, cells are released from biofilm and can disseminate into host 
tissues and initiate the formation of new biofilms in another sides. The majority of 
dispersed cells are yeast cells. This finding suggests that the transition from yeast 
cells to hyphae that occurs during the initial phase of biofilm formation is reversed 
for this step. In addition, dispersed cells have a distinct phenotype when compared 
with planktonic cells displaying elevated adherence, filamentation capacity, and 
increased pathogenicity in a disseminated infection model [165].  
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Hawser and Douglas were the first to create a model to study for C. albicans 
biofilm development in 1994 [184]. Since then, different model systems have been 
developed both in vitro and in vivo by several research groups [148,185,186].  
Quantification of biofilms is evaluated by a colorimetric assay that depends on the 
reduction of a tetrazolium salt [168,187], by [
3
H] leucine incorporation [184], or 
dry weight measurements [185]. The overall morphology and architecture of 
Candida biofilms is generally examined with fluorescence microscopy, scanning 
electron microscopy (SEM) or confocal scanning laser microscopy (CLSM) 
techniques. SEM is able to visualize detailed surface topography and morphology, 
whereas CLSM is used to give an image of the three-dimensional structure of 
biofilms and the emergence of extracellular matrix during biofilm formation [185]. 
Biofilm development is influenced by nature of the device surface, presence of a 
conditioning films, and liquid flow [150,184]. Hawser and Douglas [184] evaluated 
the ability of C. albicans to form biofilm on various catheter materials. The most 
extensive biofilm was observed for latex urinary catheters, followed by PVC and 
polyurethane. In contrast, 100% silicone was capable of significantly less biofilm 
formation. Serum, as a conditioning film, is important in the early adhesion events 
of biofilm formation, providing receptor binding sites for planktonic C. albicans 
[188], and in the interaction with Candida cells to initiate and promote biofilm 
formation and maturation [189]. The amount of matrix depends on incubation 
conditions. Gentle shaking produce a flow of liquid over the surface of the cells 
leading to an increase of the amount of the matrix, not observed in static condition. 
Similarly, matrix production is increased when conventional flow systems or 
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5.1. Standard antifungal classes  
Current therapies against Candida infections may be grouped into four classes of 
antifungal compounds: polyenes, azoles, echinocandins and nucleoside analogues. 
 
 
Figure 3. Antifungal drugs and their targets. The main classes of antifungal 
drugs that are in clinical use and how they exert their effects on the fungal cell. 
 
Polyene antifungal agents bind sterols in the fungal cell membrane and cause 
electrolyte leakage via formation of transmembrane channels [190]. A second 
proposed mechanism of action involves a cascade of oxidation reactions and 
   Chapter 1 
28 
 
interactions with lipoproteins that impair membrane permeability through the 
release of free radical. Acquired resistance to amphotericin B is relatively rare and 
biofilms are approximately eight-times more resistant to amphotericin B than their 
planktonic counterparts [191]. The specific mechanisms of resistance to polyenes 
are not known, but might involve alterations in the cell membrane composition 
[192]. 
Azoles target ergosterol biosynthesis via blockage of the fungal cytochrome P450-
dependent enzyme lanosterol 14α-demethylase encoded by the ERG11 gene. 
Although acquired resistance is not common, cells in the biofilm environment are 
up to 1000-fold more azole resistant than their planktonic counterparts, making 
azoles an ineffective option [193]. The most frequently observed resistance 
mechanisms include alteration of the target enzyme either by overexpression or as a 
result of point mutations in the gene that encodes it and upregulation of membrane-
bound efflux pumps [194]. 
Pyrimidine analogs arrest fungal DNA and RNA synthesis following their 
incorporation in a growing RNA/DNA strand. The group is solely composed of 
flucytosine. It is brought into the cell via a cytosine permease and metabolized, by 
a cytosine deaminase into a toxic version of uridine triphosphate. Flucytosine is 
also converted into a metabolite that inhibits the thymidylate synthetase, leading to 
decrease the availability of nucleotides for DNA synthesis [195]. The most 
common causes of drug resistance are mutations in the cytosine permease gene 
FCY2, or in the cytosine deaminase gene FCY1. Candida strains that are 
heterozygous for these mutations show partial resistance and can quickly acquire 
further mutations to gain full resistance upon drug exposure [196]. 
Echinocandins block the enzyme β-1,3-glucan synthase and thereby inhibit 
incorporation of β-1,3-glucans in the cell wall disturbing its integrity [132]. 
Echinocandins are the most recent advances in antifungal drug development. These 
fungicidal compounds are semi-synthetic amphiphilic lipopeptides composed of a 
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cyclic hexapeptide core linked to a variably configured lipid side chain [197]. 
Compared to planktonic cells, biofilms are approximately 2–20-fold more resistant 
[191]. The low resistance to echinocandins has been linked to acquired or intrinsic 
FKS1 point mutations in C. albicans [198,199] 
Concerning biofilms, of the classes mentioned above, only echinocandins and the 
polyene amphotericin B lipid formulations have been shown to be effectively 
active both in vitro [200,201] and in vivo [202,203]. 
 
5.2. Candida biofilm resistance mechanisms 
In the last years, the incidence of fungal infections has increased significantly. This 
is due to an increase in antimicrobial resistance and to the restricted number of 
antifungal drugs. The ability of Candida albicans to form drug resistant biofilms is 
an important factor in their contribution to human disease [163]. Recent 
investigations have started to elucidate the mechanisms behind the profound 
resistance associated with the biofilm. This resistance appears to be multifactorial, 
involving mechanisms of planktonic antifungal resistance (e.g. upregulation of 
drug efflux pumps, upregulation of target gene expression) as well as mechanisms 
specific to the biofilm lifestyle (e.g. presence of matrix, persister cells) [204]. The 
following section describes some of the main factors that play a role in fungal 
biofilm resistance. 
 Efflux pumps. Upregulation of drug efflux pumps has been described as a 
causative factor in biofilm drug resistance for several biofilm-forming 
microorganisms [205]. In C. albicans, two groups of efflux pumps have 
been shown to contribute to drug resistance: the ATP binding cassette 
(ABC) transporters encoded by the CDR-genes and the major facilitator 
(MF) superfamily encoded by the MDR genes [206]. It has been observed 
that the overexpression of efflux pumps is involved in azole resistance 
[207-209], but not in resistance to echinocardins and Amphotericin B 
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[210,211]. It has been demonstrated that transcription of both MDR1 and 
CDR1 was more abundant in 24 h C. albicans biofilms than planktonic 
cultures of the same age [193,208]. Furthermore several studies showed that 
CDR1, CDR2 and MDR1 single and double mutants are susceptible to 
azoles when grown planktonically but preserve their resistance when grown 
in a biofilm structure, suggesting that the presence of these genes is not 
necessary for resistance in biofilms [193,208,212]. In addition, these 
findings supported the hypothesis that up-regolation of efflux pumps 
contributed to resistance during the early biofilm developmental phase, but 
their role in mature biofilms appeared to be minimal. 
 Cell density. To examine the role of high cell density on biofilm drug- 
resistance, Perumal et al. [212] compared the susceptibility of planktonic C. 
albicans cells with intact and disrupted biofilms. It was demonstrated that 
both type of cells exhibited azoles, amphotericin B and caspofungin 
sensitivity at low cell numbers, but became resistant at a high cell density, 
indicating that the increased resistance was indeed associated with the 
biofilm architecture. Similar conclusions were also obtained by Seneviratne 
et al. [213] for the azole ketoconazole and the pyrimidine analog 5-
flucytosine, suggesting that even if the high cell density influences C. 
albicans antifungal resistance, this is not a feature that can be applied only 
to biofilms, since a similar trend has been detected also in planktonic cells. 
 Persister cells. The presence of persister cells in Candida biofilms was first 
shown by LaFleur et al. [214]. It has been hypothesized that the inability of 
antibiotics to kill persister cells is a consequence of the dormant state in 
which persister cells are present, since antibiotics need an active target to 
perform their function [215,216]. Furthermore, a study conducted by Khot 
et al. [217] demonstrated that these cells showed differential regulation of 
genes involved in both ergosterol (ERG1 and ERG25) and β-1,6 glucan 
   Chapter 1 
31 
 
(SKN1 and KRE1) pathways, suggesting the possibility that the transition 
to a persister cell involves changes in both cell membrane and cell wall. 
 
Figure 4. Schematic overview of fungal biofilm resistance mechanisms. The 
figure illustrates the density and complexity of the C. albicans biofilm, with 
different morphotypes present surrounded by extracellular matrix (ECM). The 
arrows represent the different factors that drive antifungal resistance within the 
biofilm, including density, stress, persisters, ECM, efflux, overexpressed targets, 
and the general physiology of the biofilm [218].  
 
 Stress. In the last years, it has been shown that drug resistance in Candida 
biofilms can be also promoted by the activation of several stress responses. 
One of the most important is the cell-wall integrity pathway. In particular, it 
was observed that the lacking of the mitogen-activated protein kinase 
(MAPK) mkc1p, which is activated by contact stress, causes the 
development of deficient biofilms with reduced filamentation and 
susceptible to MICs 100-fold lower than the sessile wild type and both 
planktonic strains [219]. Calcineurin, a Ca
2+ 
calmodulin-activated serine/ 
threonine-specific protein phosphatase plays many critical stress roles in the 
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fungal cell and it has also implicated in mediating resistance to the azoles. 
C. albicans sessile cells are up to 1,000-fold more resistant to fluconazole 
than planktonic counterparts. Inhibiting calcineurin pharmacologically or 
impairing calcineurin function, genetically increased the azoles activity 
against C. albicans indicating that inhibitors could be used in combinations 
as novel therapeutic interventions to treat or prevent biofilms [220]. 
Another stress response pathway contributing to Candida biofilm resistance 
involves a heat shock protein HSP90. Recent studies demonstrated that 
genetic depletion of Hsp90 reduced C. albicans biofilm growth and 
maturation and interestingly impaired dispersal of biofilm cells and support 
azoles susceptibility [221,222]. Furthermore, a marked decrease in matrix 
glucan levels was observed, providing that Hsp90 might regulate biofilm 
azole resistance acting as a regulator of the matrix sequestration pathway 
[222]. 
 Extracellular matrix. Biofilm matrix material may also impair drug 
delivery, either via steric hindrance or by actively binding or sequestrating 
antifungals. Comparing biofilms grown under continuous flow with 
statically grown biofilms, Al-Fattani and Douglas [181] were able to link 
Candida biofilm resistance to the production of an extracellular matrix 
[181].  Nett et al. [157] observed that planktonic cells surrounded by 
purified matrix material mimicked the biofilm drug-resistant phenotype, 
confirming the idea that matrix may prevent the reaching of antifungals to 
their intracellular target. This resistance appears to correlate with 
production of a matrix carbohydrate, β-1,3 glucan. Its contribution was 
clarified when it was shown that biofilm cell-walls bound 4- to 5 fold more 
azole than planktonic counterparts, thereby decreasing its potential to 
control biofilm-associated cells [223]. Further studies have shown that β-1,3 
glucans are also responsible for sequestering echinocandins, pyrimidines, 
   Chapter 1 
33 
 
and polyenes [224]. Since this discovery, the involvement of different genes 
in this process has been elucidated. One of these genes (FKS1), encoding C. 
albicans glucan synthase, that was found to be involved in the production of 
extracellular matrix glucan and in the biofilm drug-resistant phenotype, 
both in vitro and in an animal model [225]. Genes SMI1 and RLM1, which 
control cell-wall glucan content in response to stress, were shown to be 
essential for C. albicans matrix and cell-wall β -1,3-glucan content [226]. 
Recently, it was discovered that extracellular DNA is also an important 
component of biofilm matrix material that affects drug resistance. 
Treatment with DNAse decreased C. albicans biofilm biomass [227] and 
enhanced the activity of AmB and caspofungin but, surprisingly, had no 
impact on the activity on fluconazole [228]. 
 Physiology. The general physiological state of sessile cells may also 
influence the susceptibility profiles of biofilms [229-231]. Nevertheless, 
factors including pH, temperature, oxygen availability, and other 
environmental conditions may alter the biofilm architecture, and possibly 
antifungal sensitivity [232,233], suggesting that it is more likely that more 
complex factors are involved in biofilm resistence.  
 Overexpressed targets. The fungistatic nature of the azoles towards C. 
albicans induces surviving population to evolve drug resistance by the 
alteration of the target 1,4-α-demethylase enzyme encoded by ERG11 
through the development of point mutations or overexpression [234-236]. 
Alteration of ergosterols in biofilm membranes may explain their resistance 
to polyene-derived antifungal agents. Transcriptional analysis of biofilm 
population, 10 times more resistant to amphotericin B, for genes from the 
beta-1,6-glucan pathways indicated a possible association between the high 
level of resistance and upregulation of CaSKN1 and CaKRE1 in the biofilm 
cells compared to planktonic counterparts [237]. Furthermore, it has been 
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shown that transcriptional responses in young and mature biofilms after 
exposure to high doses of antifungals differed depending to the type of drug 
tested [238]. Exposure of both young and mature biofilms to fluconazole 
induced upregulation of genes encoding enzymes involved in ergosterol 
biosynthesis (CaERG1,CaERG3,CaERG11, and CaERG25), whereas 
treatment with amphotericin B resulted in an overexpression of 
predominantly CaSKN1, with a modest upregulation of CaKRE1. 
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Outline of the thesis 
The search for novel antimicrobial agents to combat the emerging pathogens and to 
elude increased resistance shown by others against existing antimicrobial drugs has 
drawn attention to natural products. Microbial metabolites are recognized as a 
major source of compounds endowed with potent biological activities and, among 
these, some biosurfactants have been described as alternatives to synthetic 
medicines and antimicrobial agents. Moreover, thanks to their ability to modulate 
the interaction of cells with surfaces, biosurfactants are able to interfere with 
microbial adhesion and biofilm formation, an important and mostly hazardous 
occurrence on medical devices, especially as microrganisms within such biofilms 
usually become highly resistant to drugs and adverse environmental challenges.  
Candida albicans is the major human fungal pathogen in clinical setting causing 
various clinical manifestation, from superficial to high severe widespread invasive 
infections. 
In this work, the biological activity of two biosurfactants (BS), CV8LAC BS and 
AC7 BS, was evaluated against C. albicans biofilms grown on medical-grade 
silicone elastomer disks (SEDs), at physiological conditions, in the presence of a 
proteinaceous solution, i.e. fetal bovine serum, to mimic blood contact during 
clinical use in internal body. In addition, bisurfactant AC7 activity has been 
assessed in combination with farnesol, an important quorum sensing molecule 
involved in C. albicans biofilm development. 
Biosurfactants CV8LAC, produced by Lactobacillus brevis, and AC7, from 
Bacillus subtilis, are able to reduce significantly C. albicans cell adhesion and 
biofilm formation on medical grade silicone disks. In particular, these 
biosurfactants show the highest inhibitory activity during the adhesion phase, that 
persists, although at lower levels, at further incubation times, where a still 
significant reduction of biofilm growth is observed. 
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Furthermore, both compounds do not inhibit C. albicans planktonic cells or pre-
formed biofilms, thus suggesting an anti-adhesive but not antifungal activity. In 
addition, when lipopeptide biosurfactant AC7 is used together with farnesol against 
C. albicans adhesion, growing biofilm and pre-formed biofilm, the inhibitory 
activity is significantly enhanced compared to the two compounds tested alone, 
suggesting a synergistic effect. These findings are supported also by the 
comparative ultra-structural analysis performed by SEM and CLSM on 
microorganisms grown on test and control samples. The analysis of quantitative 
SEM data on the percentage of polymer surface covered by biofilm shows lower 
values in treated samples in respect to controls. No phenotypical differences are 
indeed found in blastoconidia, hyphal morphology and budding locations. 
These results suggest that CV8LAC and AC7 biosurfactants, thanks to their ability 
to change the surface characteristics, alone or in combination with quorum-sensing 
molecules or antifungal compounds, can be considered as potential inhibitors of 
biofilm growth on medical insertional materials. 
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Inhibition of Candida albicans adhesion on medical-grade silicone 
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The study aimed at investigating the ability of biosurfactant produced by a 
Lactobacillus brevis isolate (CV8LAC) to inhibit adhesion and biofilm formation 
of Candida albicans on medical-grade silicone elastomeric disks (SEDs). 
Biosurfactant activity was evaluated at physiological conditions, by means of co-
incubation and pre-coating assays. Additionally, biosurfactant extract was tested 
for antifungal susceptibility against C. albicans in both planktonic and sessile form. 
Biofilm covered surface and hyphae and blastospores occurrence were quantified 
by scanning electron microscopy (SEM) and image analysis. Biosurfactant did not 
inhibit growth of C. albicans in both planktonic and sessile form. Nevertheless, co-
incubation with 2000 µg ml
-1
 biosurfactant significantly reduced biofilm formation 
on SEDs surface by 89%, 90% and 90% after 24, 48 and 72 h of incubation. Fungal 
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adhesion and biofilm formation to pre-coated SEDs was reduced by 62%, 53%, 
50% and 44% after 1.5, 24, 48 and 72 h. SEM showed a significant reduction of 
biofilm covered surface in pre-coated disks but no differences in the production of 
hyphae or blastospores, except at 1.5 h of incubation. This study demonstrated that 
CV8LAC biosurfactant has the ability to counteract significantly the initial 
deposition of C. albicans to silicone surfaces and to effectively slow biofilm 
growth. The anti-adhesive properties of the CV8LAC biosurfactant suggest a 




Transplantation procedures, immunosuppression, the use of chronic indwelling 
devices, and prolonged intensive care unit stays have increased the prevalence of 
fungal implant-related infections. Even with current antifungal therapy, Candida 
species causes 10% of the overall infections of intravenous catheters and cardiac 
devices prosthetic valves as well as 21% of the total cases of urinary catheters 
infection with a mortality rate of 20-40% and highly expensive costs [1]. 
Nowadays, Candida albicans is the fungus most frequently associated to medical 
devices-related infections [2-5] and its ability to form biofilms has a profound 
impact on the capacity to cause human disease. The presence of biofilm, in fact, 
protects the microorganism from host defences and reduces significantly its 
susceptibility to antifungal agents [6].  
The early phase of Candida biofilm formation, consisting in the adherence of yeast 
cells to biomaterials [7], is determined by a complex interplay of hydrophobicity, 
electrostatic interactions, and presence of specific receptor sites on the cell surface 
[8]. Macromolecular components (such as saliva, urine, or blood) adsorbed onto 
biomaterial surfaces may change the electrical properties and the hydrophobicity of 
the surface, favoring microbial colonization. Altering the chemical-physical 
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properties of this conditioning film could represent a preventive strategy to limit 
pathogens adhesion and biofilm formation on medical implantable materials [9]. 
Biosurfactants are amphipathic metabolites produced by a wide variety of 
microorganisms, with both hydrophilic and hydrophobic moieties within the same 
molecule [10]. It has been hypothesized that the adsorption of biosurfactants to a 
substratum surface may reduce its hydrophobicity, thus interfering with microbial 
adhesion and desorption processes [11]. 
Lactobacilli, which are part of the human and animal commensal intestinal flora, 
have recently caught the attention of medical and scientific researchers due to the 
extraordinary health enhancing benefits they exhibit [12-14]. These bacteria 
produce a wide variety of secondary metabolites with anti-microbial activity, such 
as hydrogen peroxide, lactic acid, and bacteriocins. In addition, lactobacilli 
interfere with the adhesion of different pathogens on epithelial cells of urogenital 
and intestinal tracts [15] and on a variety of medical devices producing adhesion 
inhibitors, such as biosurfactants [14]. 
Biosurfactants produced by lactic acid bacteria have been shown to reduce the 
initial adhesion of different bacterial pathogens and, to a lesser extent, of yeasts to 
polystyrene [16,17], silicone rubber [18, 19], surgical implants [20] and voice 
prostheses [21,22]. 
The crude biosurfactant produced by Lactobacillus brevis CV8LAC was previously 
found to be an excellent anti-adhesive agent against culture collection strains of C. 
albicans on polystyrene plates [23]. 
In this study, the ability of CV8LAC biosurfactant to inhibit adhesion and biofilm 
formation of a C. albicans strain, isolated from explanted central venous catheter, 
was evaluated on silicone elastomer at different times of biofilm growth, in 
physiological conditions, by means of the viable cell counting method and the 
biofilm was visualized and quantified by scanning electron microscopy (SEM). 
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Materials and Methods 
 
Strains 
Lactobacillus brevis CV8LAC strain was isolated from a fresh cabbage obtained 
from a producer of biological fruit and vegetables in a rural area of Piedmont, Italy 
[23]. Candida albicans 40 (DSM 29204), used for biofilm assays, is a wild strain, 
clinically isolated from a central venous catheter. L. brevis CV8LAC strain was 
cultivated in MRS broth without Tween 80
®
 (Sigma-Aldrich) and stored at −80°C 
in the same medium supplemented with 25% glycerol. C. albicans 40 strain was 
cultivated in Yeast Nitrogen Base broth (Sigma-Aldrich) with 50 mmol l
-1
 dextrose 
(Biolife) (YNBD) and stored at −80°C in Sabouraud dextrose broth (Sigma-
Aldrich) supplemented with 25% glycerol. 
 
Biosurfactant production and extraction 
For biosurfactant (BS) production, a seed culture was prepared by transferring a 
loop of L. brevis CV8LAC strain from a MRS agar (supplemented with 0.1% 
Tween 80
®
) overnight culture into 20 ml of MRS broth without Tween 80
® 
and 
incubated at 28°C for 4 h at 140 rpm. Thereafter, 2 ml were inoculated in 500 ml of 
the same broth in a 2 l flask and incubated again at 28°C for 24 h at 140 rpm. The 
culture broth was then centrifuged at 6000×g for 20 min and the supernatant 
collected. For BS extraction, the supernatant was acidified to pH 2 with 6 mol l
-1 
HCl, stored overnight at 4°C and extracted three times with ethyl acetate: methanol 
(4:1) (Sigma-Aldrich) according to the method described by Rivardo et al. [24]. 
The remaining water in the organic phase was removed by anhydrous sodium 
sulfate. The organic phase was evaporated to dryness under vacuum condition and 
acetone was added to recover raw CV8LAC BS. Acetone was, then, evaporated 
and CV8LAC BS collected and weighted. 
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Antifungal susceptibility testing against Candida albicans planktonic cells 
The effect of CV8LAC BS on planktonic cells of C. albicans 40 was evaluated 
according to EUCAST guidelines [25]. Briefly, CV8LAC BS solution (4000 µg ml
-
1
) was diluted in a 96-well microtiter plate (Bioster) with PBS to obtain final 
concentrations of CV8LAC BS ranging from 3.9 µg ml
-1 
to 2000 µg ml
-1 
in a final 
volume of 100 µl per well. C. albicans 40 suspension at the concentration of 1-
5×10
5
 Colony Forming Unit per ml (CFU ml
-1
) was prepared in sterile double-
strength RPMI 1640 medium (Sigma-Aldrich) buffered with 3-(N-morpholino) 
propanesulfonic acid buffer (MOPS) (Sigma-Aldrich) and supplemented with D-
glucose (2% final) pH 7.0. One-hundred microliters of inoculum were then added 
to each well and the microtiter plate was incubated without agitation at 37°C for 24 
h. Quadruplicate assays were performed for all CV8LAC BS concentrations used 
for test. After the incubation, the absorbance at 450 nm was determined for each 
well. 
 
Medical-grade silicone elastomeric disks preparation 
Two different sizes of medical-grade silicone elastomeric disks (SEDs) 
(TECNOEXTR S.r.l., Italy) were used in the study: 15 mm in diameter, 1.5 mm in 
thickness for experiments in 12-well culture tissue plates and 10 mm in diameter, 
1.5 mm in thickness for experiments in 24-well culture tissue plates. Each silicone 
disk was cleaned, sterilized and conditioned before use according to the method 
described by Busscher et al. [18]. Briefly, disks were submerged in 200 ml of 
distilled water supplemented with 1.4% (v/v) of RBS 50, sonicated for 5 min at 60 
kHz using Elma S30H (Elmasonic, VWR International) and rinsed in 1 l of MilliQ 
water for two times. Then, disks were submerged in 20 ml of MeOH (99%) 
(Sigma-Aldrich), rinsed twice, dried under a sterile hood and steam sterilized for 15 
min at 121°C. Before use, each silicone disk was aseptically transferred into 2 ml 
of Fetal Bovine Serum (FBS) (Sigma-Aldrich), incubated at 37°C for 24 h at 140 
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rpm and rinsed with PBS to provide for a serum protein coating simulating blood 
contact during clinical use. 
 
Antifungal susceptibility testing of Candida albicans biofilm 
The antifungal effect of CV8LAC BS on C. albicans 40 preformed biofilm was 
carried out according to Chandra et al. [26], with minor changes. Briefly, C. 
albicans 40 cells were grown for 24 h at 37°C in 25 ml of YNBD at 140 rpm. After 
centrifugation and two washings with PBS, the pellet was resuspended in the same 




. One milliliter of this fungal suspension 
was added to each well of 24-well plates (Greiner bio-one) containing a silicone 
disk. After 1.5 h (adhesion phase) in static conditions at 37°C, the disks were 
placed into new plates containing, in each well, 1 ml of YNBD and incubated for 
24 h at 37°C at 90 rpm (biofilm growth phase). Mature biofilms were transferred 
into new plates with different concentrations of CV8LAC BS ranging from 3.9 µg 
ml
-1 
to 2000 µg ml
-1
 and incubated for other 24 h at 37°C in static conditions. The 
antifungal activity of CV8LAC BS was evaluated by the XTT (Sigma-Aldrich) 
colorimetric assay. Disks covered with 48 h old C. albicans 40 biofilm were 
transferred into new plates containing 1 ml of PBS, 12.5 µl of XTT solution (1 mg 
ml
-1
) and 1 µl of menadione solution (1 mmol-Sigma-Aldrich). Plates were covered 
with aluminum foil and incubated at 37°C for 5 h at 90 rpm. Triplicates assays 
were performed for all CV8LAC BS concentrations used for the test. From each 
well, 150 µl were transferred to a 96-well plate and the absorbance was measured 
at 490 nm using a Ultramark microplate imaging system (Bio-Rad). 
 
Anti-adhesion and anti-biofilm assays 
 
Co-incubation assays 
C. albicans 40 cells were grown for 24 h at 37°C in 25 ml YNBD at 140 rpm. After 
centrifugation and two washings with PBS, the pellet was resuspended in the same 
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. One milliliter of the fungal suspension 
was added to each well of a 12-well plates (Greiner bio-one) containing a silicone 
disk together with either 1 ml of a 2× CV8LAC BS solution (4000 µg ml
-1
) (test 
samples) or PBS (control). After 1.5 h, the disks were placed into new plates 
containing in each well either 2 ml of YNBD with 0 µg ml
-1 
(control group) or 
2000 µg ml
-1 
CV8LAC BS (test group). After incubating the samples for 24, 48 and 
72 h at 37°C with gentle shaking, the supernatants were discarded and the disks 
were washed three times with PBS to remove non-adherent cells. The biofilm 
inhibition activity of CV8LAC BS was evaluated by means of the viable cell 
counting method reported below, and expressed as Colony Forming Unit per disk 
(log10 CFU/disk). Assays were carried out in triplicate. Results were expressed as 
mean values and standard deviations. 
 
Pre-coating assays 
Silicone disks were submerged in 2 ml of CV8LAC BS solution at the 
concentration of 2000 µg ml
-1 
(test group) or in PBS only (control group). All 
samples were incubated at 37°C for 24 h at 140 rpm, and then gently rinsed with 
PBS to remove non-adherent CV8LAC BS.  
C. albicans 40 cells were grown for 24 h at 37°C in 25 ml of YNBD at 140 rpm. 
After centrifugation and two washings with PBS, the pellet was resuspended in the 




. Two milliliters of fungal 
suspension were added to each well of a 12-well plate containing a disk pretreated 
with 2000 µg ml
-1
of CV8LAC BS (test group) or PBS (control group). After 1.5 h 
of adhesion phase, six disks for each group were washed three times with PBS to 
remove non-adherent cells. The other samples were transferred in new plates 
containing 2 ml of YNBD and incubated at 37°C with gentle shaking for testing 
longer incubation times at 24, 48 and 72 h. After the incubation period, disks were 
washed three times with PBS to remove non-adherent cells. The biofilm inhibition 
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activity of CV8LAC BS after 1.5 h and 24, 48, 72 h incubation was evaluated with 
the viable cell counting method described below and expressed as log10 CFU/disk. 
Assays were carried out in triplicate and experiments were repeated three times. 
Results were expressed as mean values and standard deviations. 
 
Viable cell counting 
The effect of CV8LAC BS on C. albicans 40 adhesion and biofilm formation was 
assessed by determining the viable cell counts after biofilms had been rinsed for 
three times with PBS to remove non adherent cells. Briefly, disks were inserted 
into 50 ml tubes containing 10 ml PBS and subjected to four cycles of sonication 
(30 s) and stirring (30 s). The sonication fluid with detached cells was serially 
diluted in PBS and each dilution was plated onto Sabouraud Dextrose Agar 
(Sigma-Aldrich), in triplicate. Agar plates were incubated for 24 h at 37°C and 
colonies were then enumerated. Results were expressed as log10 CFU/disk. 
 
SEM analyses 
A specific set of samples was realized according to the method applied in the pre-
coating assay for a qualitative and quantitative analysis of C. albicans 40 biofilm 
formation by scanning electron microscopy (SEM). After the specific incubation 
time, each disk was washed three times in PBS to remove the culture medium and 
non-adherent cells from the silicone substrate, fixed by immersion in aldehydic 
solution (2.5% glutaraldehyde in 0.1mol l
-1
 phosphate buffer) for 24 h at 4°C, 
washed twice in distilled water, dehydrated by immersion in ascending alcohol 
solutions (70%, 90% and 100% ethanol, 10 min each) and dried overnight under a 
laminar flow cabinet. Finally, dried samples were glued to SEM sample holder by 
double bonding carbon tape and gold sputtered. 
SEM analyses were conducted in a XL30 ESEM FEG (Fei-Eindhoven, NL) 
scanning electron microscope at a 10 KV beam voltage. A preliminary qualitative 
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investigation of the Candida biofilm was performed at a magnification ranging 
from 100× to 10000×. A representative selection of images at 1000× was stored by 
collecting the secondary electrons signal revealing fine morphological details of 
cells and extracellular matrix. 
For quantitative purposes, two sets of images were also acquired per each sample. 
A first set of nine different fields of view was obtained by collecting the 
backscattered electrons signal at a magnification of 40×, thus guaranteeing the 
observation of a total area of 64 mm
2
 at the silicone disk centre. To distinguish 
between biofilm covered surface and exposed silicone, compositional contrast was 
stressed and images were processed according to a protocol adapted from Bressan 
et al. [27]. Briefly, high resolution digital images (1936×1452 pixels) were 
acquired and then threshold by an automated routine implemented in ImageJ (NIH, 
US). The number of dark pixels associated to Candida biofilm and bright pixels 
representing the silicone surface was obtained. Percent area of the silicone disk 
covered by Candida biofilm (BA%) was computed calculating the percent ratio of 
dark pixels over the whole pixels number of the image. 
To obtain quantitative data on hyphae and blastospores occurrence on Candida 
biofilm, a second set of five SEM images per sample was acquired by collecting 
the signal from secondary electrons at a magnification of 1000×. The enumeration 
of the two features of interest was performed according to a protocol adapted from 
Lucas et al. [28]. A squared grid of 15 µm element size was superimposed to each 
acquired imaged and the observation of each single cross point allowed to quantify 
the occurrence of hyphae or blastospores. Percentage of hyphae and blastospores 
was computed over the total number of evaluated cross points. 
 
Statistical analysis of data 
Statistical analysis and graphs were elaborated by means of the statistical program 
R (R Development Core Team, http//www.R-project.org).  
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ANOVA was used to compare optical densities of C. albicans 40 planktonic cells 
and pre-formed biofilm at different CV8LAC BS concentrations. 
Welch Two Sample t-test was performed to investigate the effect of CV8LAC BS 
in co-incubation and pre-coating assays on biofilm formation at different 
incubation times. Results were considered to be statistically significant when 
P<0.05. In this case, the R package dupi R was used to estimate log10 CFU/disk 
from colony counts [29]. 
Chi-square test with Yates’ continuity correction was used to compare proportions 




Antifungal susceptibility testing on Candida albicans planktonic cells and biofilm 
CV8LAC BS susceptibility testing was carried out on C. albicans 40 planktonic 
cells and pre-formed biofilm by means of EUCAST and XTT methods, 
respectively. Optical densities at 450 nm and 490 nm versus the biosurfactant 
concentration were plotted in Fig. 1. 
One-way ANOVA was used to evaluate the role of CV8LAC BS concentration. 
While on planktonic cells a significant stimulating effect could be detected 
(P=6.5×10
-4
), on preformed biofilm no significant activity (either inhibitory or 
stimulating) could be established (P=0.89). 
By further inspection of the role of CV8LAC BS concentration on planktonic cells, 
we tried to locate the concentration cutoff that minimizes the P-value and best 
discriminates (by separating concentrations in 2 groups) the effect. We were able to 
isolate a first concentration group (ranging from 0 µg ml
-1 
to 62.5 µg ml
-1 
CV8LAC 
BS) where optical densities of planktonic cells co-incubated with biosurfactant 
were comparable to that of control (no biosurfactant added) and a second group 
(from 125 µg ml
-1 
to 2000 µg ml
-1 
CV8LAC BS), with higher optical densities, 
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where we observed a stimulating activity of CV8LAC BS starting from the 

































































Figure 1. CV8LAC BS activity at 24 h on (a) C. albicans 40 planktonic cells and 
(b) pre-formed biofilm, measured by optical density. In (a) the dashed boxes 
separate two data groups significantly different from each other (One-way 
ANOVA, P< 0.05). 
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Anti-biofilm activity of CV8LAC BS 
The anti-biofilm assays were carried out using a CV8LAC BS concentration of 
2000 µg ml
-1
. Previous studies suggested that this was the lowest concentration 
(data not shown). 
Table 1 summarizes the results of the pre-coating and co-incubation assays, carried 
out at different times (1.5 h, 24 h, 48 h and 72 h), expressed as means and standard 
deviations for log10 CFU/disk. In addition, for each time and assay, the results of 
the Welch Two Sample t-test comparing CV8LAC BS treated and control samples 
are shown. The results are reported as P-values and 95% confidence intervals for 
the differences. The final column of Table 1 indicates the percentages of inhibition 
calculated as (1-10
µ
)*100, where µ is the difference in log10 CFU/disk of BS treated 
and control samples.  
 
 
*SD: standard deviation 
†μ = (log10 CFU/disk CV8LACBS - log10 CFU/disk Control) 
‡Percentage of inhibition = (1-10μ)*100 
 
Table 1. Mean C. albicans 40 concentrations, expressed as log10 CFU/disk, 
recovered on silicone disks, 95% confidence interval, P values and inhibition 
measures, in co-incubation and pre-coating assays with CV8LAC BS. 
 
In co-incubation experiments, the number of adherent cells on control disks was 
7.500.09 log10 CFU/disk after 24h, and increased to 7.670.08 and 7.710.06 
log10 CFU/disk after 48 and 72 h of incubation, respectively. The number of 








P Inhibition measures 







Co-incubation          
 24 7.50 0.09 6.52 0.29 [-1.16, -0.78] 5.4×10-8 -0.97 89 
 48 7.67 0.08 6.67 0.08 [-1.07, -0.93] 2.6×10-19 -1.00 90 
 72 7.71 0.06 6.72 0.09 [-1.05, -0.93] 2.2×10-18 -0.99 90 
Pre-coating          
 1.5 6.10 0.21 5.68 0.24  [-0.61, -0.23] 1.4×10-4 -0.42 62 
 24 7.57 0.24 7.24 0.28  [-0.56, -0.10] 7.0×10-3 -0.33 53 
 48 7.56 0.09 7.26 0.23  [-0.46, -0.14] 1.2×10-3 -0.30 50 
 72 7.60 0.13 7.35 0.22 [-0.41, -0.09] 4.0×10-3 -0.25 44 
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increased to 6.670.08 and 6.720.09 log10 CFU/disk after 48 and 72 h of 
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Figure 2. (a) Inhibition of C. albicans 40 biofilm formation on silicone disks by 
CV8LAC BS in co-incubation assays and (b) inhibition of C. albicans 40 adhesion 
and biofilm formation on silicone disks pre-coated with CV8LAC BS, evaluated at 
1.5, 24, 48 and 72 h. White boxes: control disks; grey boxes: CV8LAC BS treated 
or co-incubated disks. 




Co-incubation with CV8LAC BS at the concentration of 2000 µg ml
-1
 induced a 
significant reduction (P<5.4×10
-8
 at least) of biofilm formation in respect to 
controls by a log10 factor ~1 (i.e. about 90%) at all times of incubation. 
In pre-coating assays, the number of adherent cells on control disks was 6.100.21 
log10 CFU/disk after 1.5 h and it gradually increased to 7.570.24, 7.560.09 and 
7.600.13 log10 CFU/disk after 24, 48 and 72 h, respectively. On BS pre-coated 
disks the number of adherent cells was 5.680.24 log10 CFU/disk at 1.5 h and then 
it gradually increased to 7.240.28, 7.260.23 and 7.350.22 log10 CFU/disk after 
24, 48 and 72 h, respectively. With respect to controls, fungal adhesion to SEDs 
treated with 2000 µgml
-1
 BS was significantly reduced by 62% at 1.5 h (P<1.4×10
-
4
) and biofilm formation after 24, 48 and 72 h of incubation was inhibited by an 
average of 50% (P<7.0×10
-3 
at least), respectively. 
CV8LAC BS activity against C. albicans 40 adhesion and biofilm formation on 
silicone disks in co-incubation and pre-coating assays at different incubation times 
is displayed in Fig. 2. Both panels show clearly that fungal adhesion and biofilm 
formation on treated disks is lower (at each incubation time) that on untreated 
disks. The difference is more evident in co-incubation assays (see again last 
column in Table 1). To be noted that in the pre-coating assay (Fig 2(b)) at time 1.5 
h fungal counts are very low compared to later times as C. albicans 40 is in the 
initial phase of adhesion. 
 
SEM analyses 
Qualitative analysis of the biofilm microstructure on high magnification SEM 
images evidenced a less compact structure of the biofilm in treated samples in 
respect to controls at 24, 48 and 72 h of incubation (Fig. 3). Moreover, a complex 
three-dimensional structure with long hyphae arranged in a multilayered network 
was found in controls at 48 and 72 h of incubation. Differently, treated samples did 
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not developed a thick hyphal network in the tested conditions. No phenotypical 
differences were found between microorganisms growth on test or control samples 
showing in both cases ovoid spherical blastoconidia with polarly or random located 
budding and true hyphae formation. No difference in the amount of extracellular 
material was documented. 
 
 
Figure 3. Scanning electron micrographs of CV8LAC BS treated (lower row) and 
control (upper row) silicone surfaces after C. albicans 40 adhesion phase (1.5 h) 
and at 24, 48 and 72 h of incubation. Original magnification 1000×. 
 
The quantification of BA% on SEDs showed differences between treated samples 
and controls (Table 2). After 1.5 h of incubation, the 33% of the control disks 
surface was covered by C. albicans 40 cells whereas, in the treated disks, only the 








Table 2. Mean C. albicans 40 biofilm covered surface evaluated by SEM and 
ImageJ (NIH, U.S.) on CV8LAC BS pre-coated and control disks 
Time 
(h) 
Biofilm covered surface (%) 
Control CV8LAC BS 
 Mean SD* Mean SD 
1.5 33 15 14 4 
24 99 0 73 13 
48 99 0 88 11 
72 100 0 95 8 




During the biofilm formation phase, control disks were totally covered by C. 
albicans biofilm (99% at 24 and 48 h, 100% at 72 h) whereas disks treated with 















































Figure 4. Percentage of blastospores detected on silicone disks pre-coated or not 
with CV8LAC BS. The dotted line represents control samples while the solid line 
represents treated samples. The vertical bars indicate the standard deviations of the 
percentages. 
 
Fig. 4 represents the percentage of blastospores in control and treated samples with 
respect to total number of hyphae and blastospores, as a function of incubation 
time. The percentage of hyphae is not reported being the complement to 100%. No 
statistically significant difference between treated samples and controls was found, 
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except at time 1.5 h where a lower proportion of blastospores (P=0.02) was 
detected in treated SEDs with respect to untreated ones. No differences in the 
production of hyphae or blastospores within the biofilm were associated with BS 
pre-coating in respect to controls at 24, 48 and 72 h. 
 
Discussion 
The high demand for new antimicrobial and antifungal agents due to the increased 
resistance of pathogenic microorganisms has drawn attention to biosurfactants as a 
new source of antimicrobial and antifungal drugs [24]. Biosurfactants have the 
ability to disrupt membranes leading to cell lysis and metabolite leakage by 
inducing changes in physical membrane structure or by disrupting protein 
conformations altering important membrane functions such as transport and energy 
generation [30, 31]. In addition, biosurfactants form a film that changes wettability 
and surface energy of the original surface affecting the adhesion properties of 
microorganisms [32]. 
In a previous work, Fracchia et al. [23] observed that CV8LAC crude biosurfactant 
was able to reduce the water surface tension from 70.92 mN m
-1
 to 47.68 mN m
-1
 
and its Critical Micellar Concentration (CMC) was 106 µgml
-1
. Furthermore, 
CV8LAC BS decreased the adhesion of two biofilm-producer strains of C. albicans 
derived from culture collections (DSMZ 11225, CA-2894) of more than 80% in 
pre-coated polystyrene microtiter plates.  
In this work, the activity of CV8LAC biosurfactant against the adhesion and 
biofilm formation of a nosocomial C. albicans isolate was assessed on medical-
grade silicone, at physiological conditions (37°C), in the presence of a 
proteinaceous solution, i.e. fetal bovine serum, to mimic blood contact during 
clinical use in internal body conditions. The efficacy of the CV8LAC BS to inhibit 
C. albicans biofilm formation was first evaluated in co-incubation experiments, 
and subsequently after its absorption on the surface of silicone disks, in order to 
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imitate a functional coating condition. In co-incubation assays, CV8LAC BS 
induced a significant reduction of biofilm formation (about 90%) at all incubation 
times. In pre-coating experiments, the highest performance was observed during C. 
albicans adhesion phase, whereas during the biofilm formation phase, the 
inhibition was lower (about 50 %) but still significant. 
Previous studies assessed the effect of biosurfactants from lactic acid bacteria 
against the initial deposition and adhesion of Candida albicans strains. Busscher et 
al. [18] demonstrated that pre-adsorption of biosurfactants from Streptococcus 
thermophilus to silicone rubber with a salivary conditioning film was effective 
against C. albicans GB 1/2 adhesion. In particular, relative initial cell deposition 
rate and C. albicans GB 1/2 cells adhering at 4 h on silicone rubber were 
respectively 69% and 77%, compared to controls (100%). In another study, a 
biosurfactant obtained from Lactobacillus acidophilus at a concentration of 1 mg 
ml
-1
 reduced the initial deposition of C. albicans strains of about 50% but it did not 
show anti-adhesive activity after 4 h in pre-coating experiments in a silicone-rubber 
bottom plate (Velraeds et al. [19]. A study from Rodrigues et al. [21] reported that 
the adsorption of a biosurfactant obtained from the probiotic bacterium L. lactis 53 
on silicone rubber reduced C. albicans deposition rate as well as the number of 
cells adhering on the surface after 4 h. The Authors also showed that C. albicans 
initial deposition and adhesion to silicone rubber treated with a biosurfactant from 
Streptococcus thermophilus A were reduced of 65% and 67-70%, respectively [22]. 
Similarly, our results suggest that CV8LAC BS has the ability to counteract 
successfully the initial adhesion of C. albicans on the pre-coated silicone surface. 
Noteworthy, we found that CV8LAC biosurfactant activity persisted at further 
incubation times, where a significant reduction of biofilm growth was observed. 
It has been supposed that biosurfactants influence bacterial-surface interactions 
thanks to their ability to change surface tension and bacterial cell-wall charge, 
affecting both cell-to-cell and cell-to-surface interactions [33]. Our results support 
the opinion that lactobacilli-derived biosurfactants remarkably affect these 
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interactions and, as a result, the surface is made less supportive for bacterial 
adhesion.  
Cultural data were also in agreement with SEM microscopic observation of the 
biofilm on silicone disks. The analysis of quantitative SEM data on the percent of 
polymer surface covered by biofilm showed lower values in treated samples in 
respect to controls. Namely, pre-coated silicone disks were characterized by a 
BA% reduction of 57% after 1.5 h and of 26%, 11% and 4.5% after 24h, 48h and 
72h respectively when compared to control disks. Quantitative data were based 
only on a bi-dimensional evaluation of the biofilm extension. The correct 
interpretation of these results should consider also the information obtained from 
the qualitative high magnification analysis, giving information on the three-
dimensional development of the biofilm. We noted a complex and well developed 
three dimensional structure controls at 48 and 72 h of incubation. This suggest that 
differences in BA% between test samples and control at 48 and 72 were probably 
underestimated by bi-dimensional image analysis. Other real three-dimensional 
imaging techniques, such as confocal laser microscopy, should be considered to 
provide data for a more exhaustive evaluation of the biofilm volume [26]. 
As many biosurfactants have been reported to show antifungal activity [16, 17], the 
effect of CV8LAC BS on C. albicans 40 planktonic cells and pre-formed biofilm 
was also evaluated. Interestingly, no antifungal activity was observed in both 
experiments at concentrations up to 2000 µg ml
-1
, suggesting that CV8LAC BS 
inhibited pathogen adhesion without affecting cell viability in planktonic and 
sessile form. These findings are in agreement with data reported by Velraeds et al. 
[19] and were supported also by the comparative ultra-structural analysis 
performed by SEM on microorganisms grown on test and control samples. No 
phenotypical differences were indeed found in blastoconidia, hyphal morphology 
and budding locations. 
Surprisingly, a raising number of C. albicans 40 planktonic cells was observed 
when the concentration of CV8LAC BS increased. Possibly, the non-purified 
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extract of biosurfactant might contain other compounds used by the microorganism 
as a source of nutrients. 
The decreased activity of CV8LAC BS on biofilm formation in pre-coating assays 
compared to co-incubation assays may be due to the strategy chosen to coat the 
silicone surface, as this was simply done by physical absorption. The biosurfactant 
molecules are attached to the surface by weak bounds (hydrogen bounds, Van der 
Walls forces) and not by covalent bounds. Hence, during the washing steps 
involved in the experimental setting, the biosurfactant might have been gradually 
removed from silicone, leading to activity loss. Physical or chemical surface 
modification will be tested in the future to bind more effectively the biosurfactant 
to the silicone and to improve and prolong anti-biofilm properties. 
Pinto et al. [34] have recently modified a Poly(dimethyl siloxane) surface by argon 
plasma treatment followed by the coating with different biosurfactants isolated 
from probiotic strains, to evaluate how these compounds affect the PDMS surface 
properties. Tested materials had no toxicity and were found to be non-hemolytic, 
indicating that the proposed approach may be effective and open new possibilities 
for the application of these surfaces in the biomedical field. 
Considering the wide selection of methods nowadays available for bonding 
biomolecules onto medical grade polymers, the anti-adhesive properties of the 
CV8LAC BS deserves a promising role as an anti-adhesive product for medical 
devices (catheters, prosthesis, stents, etc.) to effectively limit colonization and 
prevent C. albicans infections. 
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Summary 
This study investigated the properties and the activity of a lipopeptide biosurfactant 
produced by Bacillus subtilis AC7 against adhesion and biofilm formation of 
Candida albicans on medical-grade silicone elastomeric disks (SEDs). 
Biosurfactant AC7 is composed mainly of surfactin and of a lower percentage of 
fengycin, it reduces water surface tension to 30.6 nN m
1
 and its critical micelle 
concentration is 31.9 μg ml
1
. Co-incubation with 2 mg ml
1
 biosurfactant 
significantly reduced adhesion and biofilm formation of three C. albicans strains 
on SEDs in a range of 6769% after 1.5 h and of 5657% after 24h of incubation. 
On pre-coated SEDs, fungal adhesion and biofilm formation were reduced by 
5762% and 4647%, respectively. Additionally, biosurfactant AC7 did not inhibit 
growth of C. albicans strains in both planktonic and sessile form. This study 
illustrates that biosurfactant AC7 contrasts significantly the initial deposition of C. 
albicans and slows biofilm growth, suggesting a potential role of the coating for 









During the last years, a significant increase in the incidence of human fungal 
infection has been observed. Candida species are the major problem, especially in 
immunocompromised patients [1-3]. Invasive candidiasis presents a high global 
mortality rate, ranging from 36% to 63% in different patient groups [4,2], and 
represents a significant problem in terms of patient management and healthcare 
costs in the public health system [5].  
Of the Candida species isolated from humans, Candida albicans is the most 
frequently associated with the formation of biofilms on a wide variety of medical 
devices [6-9]. The ability of C. albicans to form biofilms has a profound impact on 
its capacity to cause human disease [10]. Biofilms, the most prevalent type of 
microbial growth in nature, consist in a structured surface-associated cell 
communities embedded in an extracellular matrix that have distinct phenotypes 
compared to their planktonic cell counterparts [11]. The presence of biofilm 
protects the microorganism from host defences and reduces significantly its 
susceptibility to antifungal agents [12]. Furthermore, the tenancy with which C. 
albicans infects indwelling medical devices necessitates, in almost all the cases, 
their removal. For these reasons the development of new technologies based on the 
control of the Candida sp. biofilm growth, represents the major breakthrough in the 
clinical practice and preventive medicine. The search has drawn attention on 
microbial metabolites, recognized as a major source of compounds endowed with 
potent biological activities [13]. Among these, biosurfactants have gained 
importance thanks to their interesting biological properties, such as the ability to 
disrupt membranes and to affect the adhesion properties of cells/microorganisms 
[14-17]. 
Biosurfactants are amphipathic metabolites with both hydrophilic and hydrophobic 
moieties within the same molecule which allow them to exhibit surface activities at 
interfaces [18]. In particular, lipopeptides, have steadily gained increased 




significance for their potential commercial application in pharmaceutical industries 
thanks to their promising biological characteristics such as antibacterial, antifungal 
and anti-adhesive activities [19]. Adsorption of biosurfactants to a substratum 
surface modifies its hydrophobicity, interfering with microbial adhesion and 
desorption processes [20]; in that sense, pre-coating catheters and other medical 
implantable materials with biosurfactants could be used as a preventive strategy to 
inhibit pathogenic biofilm growth, thus reducing the use of pharmaceuticals and 
antibiotics [21-23]. 
In this study, lipopeptide biosurfactant AC7 (AC7 BS) was characterized and its 
ability to inhibit adhesion and biofilm formation of tree different C. albicans strains 
was evaluated on silicone elastomer at different times of biofilm growth, in 
physiological conditions, by means of the crystal violet staining and the viable cell 
counting methods. 
 
Materials and Methods 
 
Strains 
The endophytic biosurfactant producing strain AC7 was isolated from the inside of 
stems of Robinia pseudoacacia and was genotypically identified as Bacillus 
subtilis. For biofilm assays, the strain Candida albicans IHEM 2894, isolated from 
human tongue, was purchased from The Belgian Co-ordinated Collections of 
Microorganisms (BCCM), Candida albicans 40 (DSM 29204) and 42 (DSM 
29205) are two wild strains, clinically isolated from central venous catheter and 
urinary catheter, respectively. Strain AC7 was stored at  80°C in a Luria Bertani 
(LB) broth (Sigma-Aldrich) supplemented with 25% glycerol and grown on LB 
plate for 24 h at 28°C. C. albicans strains were stored at  80°C in Sabouraud 
dextrose broth (Sigma-Aldrich) supplemented with 25% glycerol and grown for 24 
h at 37°C on Sabouraud Dextrose Agar (SDA) plates. 




Critical micelle concentration, emulsification index and stability study of AC7 BS 
 AC7 BS crude extract was obtained according to the method described by Rivardo 
et al. [24]. Surface tension of a 0.5 mg ml
1
 AC7 BS solution in alkaline distilled 
water was measured by using a ring tensiometer (KSV Sigma 703D). Results for 
surface tension measurements were expressed as mN m
1
 and compared with 
alkaline distilled water. Critical micelle concentration (CMC) was determined on 
serially diluted biosurfactant solutions in alkaline distilled water (from 0.01 mg 
ml
1
 to 0.5 mg ml
1
). Surface tension of each dilution was determined in triplicate. 
The CMC was assessed from the intercept of two straight lines extrapolated from 
the concentration-dependent and concentration-independent sections of a curve 
plotted between biosurfactant concentration and surface tension values.  
The heat/cold stability of 0.5 mg ml
1
 AC7 BS solution was evaluated by 
measuring E24 and surface tension after treatment at 100°C for 1 h, at 121°C for 15 
min and at  80°C for 24 h. To study pH stability, the pH of the AC7 BS solution 
(0.5 mg ml
1
) was adjusted to different pH values (3-11) with 1 M NaOH or 1M 
HCl. After 1 h, the surface tension and the ability to form emulsion were measured. 
Measurements were carried out in triplicate. 
 
Chemical characterization of AC7 BS  
The chemical characterization of the crude extract was developed according to the 
method described by Pecci et al. [25] and slightly modified. Liquid 
chromatography-mass spectrometric (LC-ESI-MS) analyses were performed with a 
Surveyor HPLC coupled on line with a LCQ DECA XP Plus (Thermo Finnigan) 
Ion Trap mass spectrometer equipped with an ESI source. Separations were 
performed on the analytical Luna 5 μm C18(2), 150 × 4.6 mm (Phenomenex, 
Torrance, CA) protected with a C18-Security Guard cartridge, 4 × 3.0 mm 
(Phenomenex). The mobile phase components were: A = water, 1% formic acid; B 
= acetonitrile; the lipopeptides were eluted according to the following linear 




gradient: A: B (70 : 30) for 4 min, then A : B (0 : 100) over 20 min and then 100% 
B over 6 min at flow rate of 0.8 ml min
1
. The mass spectrometer was operated in 
positive ESI (electrospray ionization) mode with a spray voltage of 5.30 kV. The 
capillary temperature was maintained at 350°C and nitrogen was used as nebulizing 
gas at 30 arbitrary units. Alternatively, liquid chromatography-tandem mass 
spectrometry (LC/ESI-MS/MS) modalities were applied to the selected precursor 
ions, following the conditions set during the infusion analysis. 
 
Antifungal susceptibility testing against Candida albicans planktonic cells 
The effect of AC7 BS on planktonic cells of C. albicans strains was evaluated 
according to EUCAST guidelines [26]. Briefly, 100 µl of AC7 BS solutions (from 
0.06 mg ml
1 
to 6 mg ml
1
) were added in a 96-well microtiter plate (Bioster). C. 





 were prepared in sterile double-strength RPMI 1640 medium 
(Sigma-Aldrich) buffered with 3-(N-morpholino)propanesulfonic acid buffer 
(MOPS) (Sigma-Aldrich) and supplemented with D-glucose (2% final 
concentration), pH 7.0. One-hundred microliters of inoculum were then added to 
each well to obtain final concentrations of AC7 BS ranging from 0.03 to 3 mg ml
1
 
in a final volume of 200 µl/well. Finally, the microtiter plate was incubated without 
agitation at 37°C for 24 h. Triplicates assays were performed for all AC7 BS 
concentrations used for test. After the incubation, OD450 was determined for each 
well using a Ultramark Microplate Imaging System (Bio-Rad). 
 
Medical-grade silicone elastomeric disks preparation 
Two different sizes of medical-grade silicone elastomeric disks (SEDs) 
(TECNOEXTR S.r.l., Italy) were used in the study: 15 mm in diameter, 1.5 mm in 
thickness for experiments in 12-well culture tissue plates and 10 mm in diameter, 
1.5 mm in thickness for experiments in 24-well culture tissue plates. Each silicone 




disk was cleaned, sterilized and conditioned before use, according to the method 
described by Busscher et al. [27]. Briefly, disks were submerged in 200 ml of 
distilled water supplemented with 1.4% (v/v) of RBS 50, sonicated for 5 min at 60 
kHz using Elma S30H (Elmasonic, VWR International) and  rinsed in 1 l of MilliQ 
water for two times. Then, disks were submerged in 20 ml of MeOH (99%) 
(Sigma-Aldrich), rinsed twice, dried under the hood and steam sterilized for 15 min 
at 121°C. 
 
Antifungal susceptibility testing of Candida albicans biofilm 
C. albicans cells were grown for 24 h at 37°C onto SDA plates. Cells were 





. One milliliter of this fungal suspension was added to each well of 24-
well plates (Greiner bio-one) containing a silicone disk. After 1.5 h (adhesion 
phase) in static conditions at 37°C, each disk was placed in 1 ml of YNBD with 
10% of FBS and incubated at 37°C for 24 h at 90 rpm (biofilm growth phase). 
Mature biofilms were then treated with different concentrations of AC7 BS in 
YNBD + 10% FBS (ranging from 0.06 to 3 mg ml
1
) and incubated for other 24 h 
at 37°C in static conditions. The antifungal activity of BS was evaluated by the 
XTT (Sigma-Aldrich) colorimetric assay. Disks were submerged in 1 ml of PBS 
containing 12.5 µl of XTT solution (1 mg ml
1
) and 1 µl of 1 mM menadione 
solution (Sigma-Aldrich). Plates were incubated at 37°C for 5 h at 90 rpm. 
Triplicates assays were performed for all AC7 BS concentrations used for the test. 
From each well, 150 µl were transferred to a 96-well plate and the absorbance was 









Anti-adhesion and anti-biofilm assays against C. albicans strains 
 
Co-incubation assays 





) in PBS + 20% FBS, were added to each well of a 24-well plates 
(Greiner bio-one) containing a silicone disk together with either 500 µl of 2× 
AC7BS solutions (1, 2, 4 and 6 mg ml
1
) (test groups) or PBS (control group). 
After 1.5 h of incubation (C. albicans adhesion phase), the disks were placed in 
either 1 ml of YNBD + 10% FBS with 0 mg ml
1
 (control group) or 0.5, 1, 2, 3 mg 
ml
1
 AC7 BS (test groups) and incubated for 24 h at 37°C at 90 rpm. The reduction 
of adherent cells and biofilm biomass was evaluated after 1.5 h and 24 h by crystal 
violet (CV) staining. The supernatants were discarded and the disks were washed 
three times with PBS to remove non-adherent cells. Afterwards, disks were dried at 
37°C for 2 h and submerged into 2 ml of a 0.2% CV solution for 10 min. The CV 
solution was removed by washing with distilled water and the disks air-dried. 
Finally, bound CV was released by adding 2 ml of 33% acetic acid (Sigma-
Aldrich) and OD570 was measured. Assays were carried out in triplicate and the 
experiments were repeated two times. Results were expressed as mean values and 
standard deviations.  
 
Pre-coating assays 
Silicone disks were submerged in 2 ml of AC7BS solution at concentrations 
ranging from 0.5 to 3 mg ml
1
 (test groups) or in PBS only (control group) at 37°C 





, were added to each well of 12-well plates containing disks 
pretreated with AC7 BS (test groups) or PBS (control group). After 1.5 h of 
incubation (adhesion phase), the disks were transferred into 2 ml of YNBD + 10% 
FBS and incubated at 37°C with gentle shaking for 24 h. The reduction of adherent 




cells and biofilm biomass were evaluated after 1.5 h and 24 h with CV staining as 
indicated previously.  
Furthermore, the anti-adhesion and anti-biofilm activity of AC7 BS pre-coating 
was evaluated by means of the viable-cell counting method at the concentration of 
2 mg ml
1
. Silicone disks and C. albicans suspensions were prepared as described 
in the previous experiment. After 1.5 h or 24 h of incubation, the supernatants were 
discarded and the disks were washed three times with PBS to remove non-adherent 
cells. Then, the disks were inserted into 50 ml tubes containing 10 ml PBS and 
subjected to four cycles of sonication (30 s) and stirring (30 s) for cells detachment. 
The disrupted biofilm cells were serially diluted in PBS and 1 ml of each dilution 
was included into melted SDA (Sigma-Aldrich) using the pour-plate method.  
Agar plates were incubated at 37°C for 24 h and colonies were then enumerated. 
Assays were carried out in triplicate and experiments were repeated two times. 
Results were expressed as mean log10 CFU/disk ± standard deviations. 
 
Statistical analysis of data 
Statistical analysis and graphs were elaborated by means of the statistical program 
R, 3.1.2 (R Development Core Team, http//www.R-project.org).  
Two-way ANOVA followed by Tukey Honest Significant Difference (HSD) was 
used to compare optical densities of planktonic cells and pre-formed biofilm at 
different AC7 BS concentrations for the three C. albicans strains.  
Welch Two Sample t-test was performed to investigate the effect of AC7 BS on the 
three Candida stains adhesion and biofilm formation in pre-coating assays, carried 
out by means of the viable cell counting method. Results were considered to be 
statistically significant when p < 0.05. In this case, the R package dupi R was used 
to estimate log10 CFU/disk from colony counts [28]. 
 
 






Critical micelle concentration and stability study of AC7 BS  
CMC was evaluated on the AC7 BS crude extract. AC7 BS solution at a 
concentration of 0.5 mg ml
1
 reduced the surface tension of alkaline distilled water 
from 72.4 to 30.6 mN m
1
. Serial dilutions of this solution showed a gradual 
increase of surface tension up to 38.2 mN m
1
 at the concentration of 62.5 μg ml
1
. 
Then, surface tension rapidly increased to 54.9 mN m
1
 at the concentration of 7.8 
μg ml
1













aSD: standard deviation 
Table 1. Surface tension and E24 of AC7 BS as a function of pH. Surface tension of 




AC7 BS at a concentration of 0.5 mg ml
1
 showed an E24 of 60%. The E24 was not 
altered by heat/cold treatments. In particular, the extract maintained the 
emulsification property even after treatment at 100°C for 1 h, at 121°C for 15 min 
and at  80°C for 24 h, and the emulsion remained indefinitely stable. Furthermore, 
the head/cold treatments did not alter the ability of AC7 BS solution to decrease 
AC7 BS (0.5 mg ml-1) 




 Mean SDa  
3.0 49.01 0.35 0 
4.0 49.40 0.29 0 
5.0 37.53 0.39 0 
6.0 28.45 0.10 9.3 
7.0 30.50 0.17 60.5 
8.0 30.95 0.18 60.5 
9.0 30.96 0.14 60.5 
10.0 31.13 0.22 60.5 
11.0 30.76 0.32 60.5 




water surface tension. Studies on the pH stability of AC7 BS demonstrated that it 
was stable over a wide pH range (Table 1).  
The highest surface activity was found between pH 6.0 (28 mN m
1
) and pH 11.0 
(30.76 mN m
-1
). The E24 of AC7 BS was not altered at pH values from 7 to 11, but 
it was strongly reduced at pH 6 (9.3%) and absent at pH 3-5.  
 
Chemical characterization of AC7 BS 
The LC/ESI-MS analysis of the crude extract showed the presence of the 
homologues of two lipopeptide families, surfactin and fengycin, respectively. 
Surfactin family resulted composed mainly of C13, C14 and C15 surfactin 
homologues, whose structures were confirmed by the product ion spectra of the 
sodiated molecules [M + Na] + at m/z 1030, 1044 and 1058. Fengycin family 
resulted composed of two main fengycin isoforms corresponding to C17 fengycin 
A and C17 fengycin B, whose structures were confirmed by the product ion spectra 
of the protonated molecules [M + H]+ at m/z 1478 and 1506, respectively. The 
relative amount of the two families in the crude extract was about 98% of surfactin 
and 2% of fengycin.  
 
Antifungal susceptibility testing on Candida albicans planktonic cells and biofilm 
AC7 BS susceptibility testing was carried out on C. albicans 40, 42, IHEM 2894 
planktonic cells and pre-formed biofilms by means of EUCAST and XTT methods, 
respectively. Optical densities at 450 nm and 490 nm versus the biosurfactant 
concentration were plotted in Figure 1. ANOVA analysis indicated that both OD450 
and OD490 were not significantly associated to biosurfactant concentrations, 
showing that no antifungal activity against planktonic cells or biofilms was 
detected for any of the strains. For biofilm, two-way ANOVA showed that OD490 
was significantly different for the three strain (p = 0.006371) but not for AC7 BS 




concentrations. Tukey's HSD method showed that the strain C. albicans IHEM 
2894 is a stronger biofilm producer.  







































Figure 1. AC7 BS activity at 24 h on (a) C. albicans 40, C. albicans 42 and C. 
albicans IHEM 2894 planktonic cells and (b) pre-formed biofilm, measured by 
OD450 and OD490, respectively.  
 
Anti-adhesion and anti-biofilm activity of AC7 BS against Candida albicans 
strains 
The anti-adhesion and anti-biofilm activity of AC7 BS concentrations ranging from 
0.5 mg ml
1
 to 3 mg ml
1
 in co-incubation and in pre-coating conditions were 
evaluated by the CV staining method. Figures 2 and 3 show the OD570 as a function 




of the biosurfactant concentration. The different scales on the y-axes are due to the 
progressive biofilm formation. 
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Figure 2. Inhibition of C. albicans 40, C. albicans 42 and C. albicans IHEM 2894 
adhesion and biofilm formation on silicone disks by different concentrations of 
AC7 BS in co-incubation assays, respectively at (a) 1.5 h and (b) 24 h incubation 
evaluated by means of the CV method. The inhibition of adhesion and biofilm 
formation is measured by OD570; each scatterplot includes a Loess curve (local 
regression curve) and a Loess confidence region (95%). 
 
In the co-incubation experiment, the trend is always realized by a U–shaped curve 
(Figure 2). The adhesion and biofilm formation of the three C. albicans strains to 
SEDs (as measured by OD570) were progressively reduced as a function of 




biosurfactant concentrations, with a minimum reached at a concentration range 
between 1 and 2 mg ml
-1
 at time 1.5 h, and at concentration of 2 mg ml
-1
 at time 24 
h. At the highest concentration (3 mg ml
-1
), C. albicans adhesion and biofilm 
formations slightly increased.  
Percentages of reduction of OD570 are reported in Table 2. In particular, the 
reduction at 2 mg ml
-1
 ranged (among the three strains) between 67% and 69% at 
1.5h, and between 56% and 57% at 24 h.  
Two-way ANOVA shows that at time 1.5 h adhesion is significantly dependent on 
concentration (but not on the strain) while at time 24 h biofilm formation is 
significantly dependent on concentration and on the strain. In particular, Tukey’s 
HSD test reveals a significant reduction (both at time 1.5 h and at time 24 h) with a 





Strain Time (h) 
  1.5 24 
  AC7 BS concentration (mg ml-1) 
 
 0.5  1  2  3  0.5  1  2  3  
Co-incubation C. albicans 40  35 63 69 51 26 47 57 49 
 C. albicans 42 32 63 67 53 23 40 55 50 
 C. albicans IHEM 2894 32 62 68 51 27 45 57 55 
Pre-coating  C. albicans 40 22 36 63 48 10 26 50 32 
 C. albicans 42 20 31 59 41 10 26 47 32 




Percentages of inhibition of C. albicans 40, C. albicans 42 and C. 
albicans IHEM 2894 adhesion and biofilm formation in co-incubation and pre-
coating experiments at different AC7 BS concentrations. 
 
 Pre-coating assays were carried out at first by CV staining using AC7 BS 
concentrations ranging from 0.5 mg ml
1
 to 3 mg ml
1
 (Figure 3). In this case, as 
well, the trend is always realized by a U–shaped curve. The adhesion and biofilm 
formation of the three C. albicans strains to SEDs were progressively reduced as a 
function of biosurfactant concentrations, with a minimum reached at the 




concentration of 2 mg ml
-1
 at both incubation times. As previously, at the highest 
concentration (3 mg ml
-1
), adhesion and biofilm formations slightly increased. 
Percentages of reduction of OD570 are reported in Table 2. In particular, at 2 mg ml
-
1 
the mean reduction ranged (among the three strains) between 59% and 63% at 
1.5h, and between 47% and 50% at 24 h.  
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Figure 3. Inhibition of C. albicans 40, C. albicans 42 and C. albicans IHEM 2894 
adhesion and biofilm formation on silicone disks by different concentrations of 
AC7 BS in pre-coating assays, respectively at (a) 1.5 h and (b) 24 h incubation 
evaluated by means of the CV method. The inhibition of adhesion and biofilm 
formation is measured by OD570; each scatterplot includes a Loess curve (local 
regression curve) and a Loess confidence region (95%). 




Two-way ANOVA shows that at 1.5 h adhesion is significantly dependent on AC7 
BS concentration and also on the strain while at 24 h biofilm formation is 
significantly dependent on concentration (but not on the strain). In particular, 
Tukey’s HSD test reveals a significant reduction (both at time 1.5 h and at time 24 





aSD: standard deviation 
bμ = (log10 CFU/diskAC7 BS  log10 CFU/diskControl) 
cPercentage of inhibition = (110μ)*100 
 
Table 3. Mean C. albicans 40, C. albicans 42 and C. albicans IHEM 2894 
concentrations recovered on silicone disks, 95% confidence interval, p values and 




The effect of SEDs pre-coating with AC7 BS concentration of 2 mg ml
1 
was 
further investigated by the viable cell counting method. Table 3 summarizes the 
results obtained for the three C. albicans strains expressed as means and standard 
deviations for log10 CFU/disk. In addition, the results of the Welch Two Sample t-
test comparing AC7 BS treated and control samples are reported as p values and 
95% confidence intervals for the differences. The final column of Table 3 indicates 
the percentages of inhibition calculated as (1-10
µ
)*100, where µ is the difference in 
log10 CFU/disk of BS treated and control samples. The number of adherent vital 
cells on control disks after 1.5 h was 6.66 log10 CFU/disk for C. albicans 40, 6.66 
log10 CFU/disk for strain 42 and 6.67 log10 CFU/disk for strain IHEM 2894, and 
increased to 7.63 log10 CFU/disk for C. albicans 40, 7.63 log10 CFU/disk for strain 
42 and 7.63 log10 CFU/disk for strain IHEM 2894 after 24 h. On AC7 BS pre-
Time 
(h) 




p Inhibition measures 
  Mean  SDa  Mean  SD    μb 
Percentage of 
inhibition (%)c 
1.5 C. albicans 40 6.66 0.0489 6.24 0.0534 [0.371, 0.471] 3.76 × 10-12  0.42 62.0 
 C. albicans 42 6.66 0.0693 6.29 0.1130 [0.278, 0.469] 1.07 × 10-6  0.37 57.7 
 C. albicans IHEM 2894 6.67 0.0595 5.26 0.0757 [0.333, 0.470] 2.19 × 10-9  0.4 60.3 
24 C. albicans 40 7.63 0.0455 7.35 0.0918 [0.188, 0.384] 1.99 × 10-4  0.29 48.3 
 C. albicans 42 7.63 0.0408 7.36 0.0601 [0.206, 0.328] 1.36 × 10-6  0.27 45.9 
 C. albicans IHEM 2894 7.63 0.0508 7.35 0.0384 [0.222, 0.339] 1.45 × 10-6  0.28 47.6 




coated disks, the number of adherent cells at 1.5 h was 6.24 log10 CFU/disk for C. 
albicans 40, 6.29 log10 CFU/disk for strain 42 and 6.26 log10 CFU/disk for strain 
IHEM 2894 and it increased to 7.35 log10 CFU/disk for C. albicans 40, 7.36 log10 
CFU/disk for strain 42 and 7.35 log10 CFU/disk for strain IHEM 2894 after 24h.  
With respect to controls, the adhesion of the three fungal stains to SEDs treated 
with 2 mg ml
1
 AC7 BS was significantly reduced in a range of 57.7-62.0% at 1.5 
h and biofilm formation was significantly inhibited in a range of 45.9-47.6% after 
































Figure 4. Inhibition of C. albicans 40, C. albicans 42 and C. albicans IHEM 2894 
adhesion (1.5 h) and biofilm formation (24 h) on silicone disks by AC7 BS (2 mg 
ml
1
) in pre-coating assays evaluated by means of the viable-cell counting method. 
 
AC7 BS activity against C. albicans 40, 42 and IHEM 2894 adhesion and biofilm 
formation on silicone disks in pre-coating assays is displayed in Figure 4. The 
comparative boxplots show clearly that fungal adhesion and biofilm formation on 
treated disks is significantly lower (at both incubation times) than on untreated 
disks. The difference is more evident at time 1.5 h. To be noted that, at time 1.5 h, 
fungal counts are very low compared to 24 h as C. albicans stains are in the initial 
phase of adhesion.  Two-ways ANOVA confirms that C. albicans viable counts are 




significantly dependent on the disk treatment (untreated or AC7 BS pre-coated) and 
on incubation time (p < 10
-15
).   
 
Discussion 
Candida albicans is one of the most important nosocomial pathogens frequently 
involved in implanted device-associated infection [29] and represents a serious 
public health problem with important medical and economic consequences [30,31]. 
There is, therefore, the need of biomaterials with antimicrobial-coated surfaces for 
the inhibition of the microbial adhesion and the eradication of biofilms. To obtain 
surfaces with permanent antimicrobial properties, polymeric surfaces have been 
modified with functional coating layers via direct covalent coupling of different 
type of molecules [32]. Main drawbacks of antimicrobial coatings arise from time 
limited effectiveness and potential toxicity towards human cells [33,34]. 
In this context, biosurfactants have recently emerged as a potential new generation 
of anti-adhesive and antimicrobial agents with enhanced biocompatibility [14]. 
Among biosurfactants, lipopeptides form the most widely reported class with 
antimicrobial activity due to their ability to disrupt phospholipidic membranes and 
to affect cell to surface interactions by decreasing hydrophobicity and, thus, 
interfering with cell deposition processes and microbial adhesion [21].  
In this study, the endophytic strain Bacillus subtilis AC7 was found to be a good 
biosurfactant and bioemulsifier producer. Surface tension, CMC and emulsification 
capacity of AC7 BS were comparable to those observed for other lipopeptide 
biosurfactants [35,36]. Moreover, AC7 BS showed a high stability over a wide 
range of temperatures and pH, similarly to what observed by Ghojavand et al. [37] 
for the biosurfactant produced by B. subtilis PTCC 1696 and by Kim et al. [38] for 
the lipopeptide biosurfactant from B. subtilis C9. Chemical analysis of the crude 
extract revealed the presence of surfactin and fengycin, as found for other 
lipopeptide biosurfactants [24,25,39,40]. 




As lipopeptide biosurfactants have been often reported to show antifungal activity 
[41-44], the effect of AC7 BS on C. albicans 40, C. albicans 42 and C. albicans 
IHEM 2894 planktonic cells and pre-formed biofilms was evaluated. Interestingly, 
no antifungal activity was observed, in both experimental conditions, at 
concentrations up to 3 mg ml
-1
, suggesting that AC7 BS inhibited pathogen 
adhesion without affecting cell growth. Similarly, biosurfactants from 
Lactobacillus brevis CV8LAC [45] and from Bacillus licheniformis V9T14 [46] 
were reported to have anti-biofilm but not antimicrobial activity. 
The anti-adhesion and anti-biofilm activity of AC7 BS against the three different C. 
albicans strains was evaluated on medical-grade silicone, at physiological 
conditions (37 °C), in the presence of a proteinaceous solution, i.e. fetal bovine 
serum, to mimic blood contact during clinical use in internal body conditions.  
The efficacy of AC7 BS, at different concentrations, to inhibit C. albicans biofilm 
formation on SEDs was first evaluated in co-incubation experiments, and 
subsequently after its absorption on the surface of silicone disks, in order to imitate 
a functional coating condition. AC7 BS treatment resulted in a significant reduction 
of the total adherent cells and biofilm biomass compared to controls for all the 
three C. albicans strains, as evaluated by the CV method. The anti-adhesive and 
anti-biofilm activity of AC7 BS was concentration-dependent, with a maximum 
activity observed at about 2 mg ml
-1
, both in co-incubation and pre-coating 
conditions. The effect of SEDs pre-coating with this concentration of biosurfactant 
was, thus, further investigated by the viable cell counting method. Cell adhesion 
and biofilm formation were significantly altered by AC7 BS treatment in terms of 
difference in the number of log10 CFU/disk. Notably, in pre-coating assays, the 
percentages of reduction were almost similar for CV and the viable cell counting 
based biofilm quantification assays (about 60% reduction of adhesion and 50% 
reduction of biofilm formation for all the three stains).  




In general, the highest performance of AC7 BS was observed during C. albicans 
adhesion phase, whereas during the biofilm formation phase, the inhibition was 
lower but still significant.  
Janek et al. (2012) demonstrated that a cyclic lipopeptide, named Pseudofactin II, 
lowered the adhesion of two C. albicans strains on different types of surfaces. The 
pre-treatment of polystyrene with pseudofactin II strongly inhibited C. albicans 
adhesion (> 90%), whereas the post-adhesion treatment dislodged biofilms grown 
on untreated surfaces at a lower extent (29-39%). In addition, both the pretreatment 
of silicone urethral catheters with pseudofactin II and the inclusion of the 
biosurfactant in the growth medium caused an efficient reduction of C. albicans 
biofilm growth. Very recently, Rautela et al. [44] evaluated the influence of 
lipopeptides from Bacillus amyloliquefaciens strain AR2 on Candida albicans 
biofilm grown in polystyrene plates. Biosurfactant exhibited concentration-
dependent fungal growth inhibition and fungicidal activity. Moreover, when added 
to the growth media, biosurfactant inhibited C. albicans biofilm formation in a 
range of 46–100 % (depending on the concentration and on Candida strains) and, 
less efficiently, dislodged preformed biofilm from polystyrene plates. 
In this study, the highest percentages of inhibition of C. albicans adhesion and 
biofilm formation on silicone were observed in the AC7 BS co-incubation assay. 
The lower activity of AC7 BS in pre-coating assays may be due to the strategy 
chosen to coat the silicone surface. By a physical absorption strategy, biosurfactant 
molecules are not covalently bound to surfaces but simply attached to the surface 
with hydrogen bounds and Van der Walls forces. Hence, during the transferring 
steps involved in the experimental setting, the biosurfactant film might have been 
gradually removed from silicone, leading to activity loss. Physical or chemical 
surface modification will be tested in the future to bind more effectively the 
biosurfactant to the silicone and to improve and prolong anti-biofilm properties. 
Pinto et al. (2011) have recently modified a Poly(dimethyl siloxane) surface by 
argon plasma treatment followed by the coating with different biosurfactants 




isolated from probiotic strains, to evaluate how these compounds affect the PDMS 
surface properties. Tested materials had no toxicity and were found to be non-
hemolytic, indicating that the proposed approach may open new possibilities for 
the application of these surfaces in the biomedical field.  
In conclusion, the lipopeptide AC7 BS, thanks to its anti-adhesive properties, could 
represent a potential candidate to effectively limit colonization of medical devices 
and prevent C. albicans infections. 
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The aim of the present study was to investigate the ability of AC7 lipopeptide 
biosurfactant (AC7 BS), alone or in combination with farnesol, to ihnibit Candida 
albicans biofilm formation on medical-grade silicone elastomeric disks in 
simulated physiological conditions. AC7BS significantly reduced the adhesion of 
three C. albicans strains up to 42% at 1.5 h and biofilm formation up to 35% and 
29% at 24 h and 48 h, respectively. Farnesol significantly reduced adhesion up to 
46% at 1.5 h and biofilm formation up to 81% and 28% at 24 h and 48 h, 
respectively. AC7BS in combination with farnesol significantly reduced adhesion 
up to 74% at 1.5 h and biofilm formation up to 93% and 60% at 24 h and 48 h, 
respectively. SEM and CLSM confirmed cultural results. In particular, SEM 
showed a significant reduction of biofilm covered surface. 




Lipopeptide biosurfactant AC7 is able to reduce significantly C. albicans cell 
adhesion and biofilm formation on medical grade silicone disks. Moreover, when 
AC7 BS is used in combination with farnesol a synergistic effect is obtained. These 
results suggest that AC7 BS, thanks to its ability to change surface characteristics, 
alone or in combination with quorum-sensing molecules, can be considered a 
potential inhibitor of biofilm growth on medical insertional materials. 
 
Introduction 
Candida albicans is part of the normal human flora, and it grows on mucosal 
surfaces in healthy individuals. In susceptible hosts, this organism causes 
approximately 50% of cases of candidemia and at least 80% of cases of 
oropharyngeal and vulvovaginal candidiasis [1]. Nowadays C. albicans is the 
fungus most frequently associated with the formation of biofilms on a wide variety 
of medical devices (such as venous or urinary catheters, endotracheal tubes, dental 
prostheses, and other indwelling devices) [2]. This ability has a profound impact on 
C. albicans capacity to cause human disease [3]. Development of new technologies 
based on the control of the Candida spp. biofilm growth is foreseen as a major 
breakthrough in the clinical practice and preventive medicine. In vitro, experiments 
showed that formation of C. albicans biofilm is a complex process involving 
multiple regulatory mechanisms. Initially, yeast cells adhere to a surface and form 
microcolonies. Afterwards, these cells form filaments and produce an extracellular 
matrix until a mature biofilm with a real three-dimensional structure is formed 
[3,4]. The presence of biofilm may protect the microorganism from host defenses, 
as well as significantly reduce its susceptibility to antifungal agents [5].  
It has been demonstrated that quorum-sensing plays an important role in C. 
albicans biofilm development [6]. C. albicans planktonic cells secrete an 
autoregulatory sesquiterpene, named E,E-Farnesol which acts as a quorum-sensing 
molecule (QSM) [7]. A lot of biofilm development stages are influenced by this 




QSM, such as the attachment of cells to the substratum, the biofilm architecture 
and the dispersal of cells from biofilm. In particular, biofilm formation is limited 
by farnesol which inhibits hyphal growth and the expression of morphology-
specific genes, regulating, yeast-to-mycelium conversion thus leading to a decrease 
of biofilm size [8]. However, the use of farnesol is not definitive in avoiding fungal 
adhesion and biofilm development on device surfaces, demanding for new or 
integrative approaches in prevention and treatment of Candida biofilm formation. 
Recent studies have drawn attention to bacterial antagonistic products [9]. Among 
these, biosurfactants have gained importance thanks to their interesting biological 
properties, such as antibacterial, antifungal and anti-adhesive activities [10-14]. 
Biosurfactants are amphipathic compounds, with both hydrophilic and hydrophobic 
moieties present within the same molecule which allow them to exhibit surface 
activities at interfaces [15]. Numerous investigations have lead to the discovery of 
many interesting chemical and biological properties of biosurfactants and several 
pharmaceutical and medical applications have been envisaged [15-17]. In 
particular, their ability to destabilize membranes by disturbing their integrity and 
permeability leading to metabolite leakage and cell lysis [18-24], as well as their 
propensity to partition at the interfaces, modifying surface properties and thus 
affecting microorganisms adhesion, are important functions for antimicrobial and 
antibiofilm applications [25]. 
Aim of the present study was to investigate the ability of a lipopeptide 
biosurfactant AC7 (AC7 BS) in combination with farnesol to inhibit different 
stages of Candida albicans biofilm development on medical-grade silicone 
elastomeric disks, at physiological conditions, by means of the viable cell counting 
method. Futhermore, adherent cells and biofilm were visualized and quantified by 








Materials and Methods 
 
Strains 
The endophytic biosurfactant producing strain AC7 was isolated from the inside of 
stems of Robinia pseudoacacia and was genotypically identified as Bacillus 
subtilis. For biofilm assays, the strain Candida albicans IHEM 2894, isolated from 
human tongue, was purchased from The Belgian Co-ordinated Collections of 
Microorganisms (BCCM), Candida albicans 40 (DSM 29204) and 42 (DSM 
29205) are two wild strains, clinically isolated from central venous catheter and 
urinary catheter, respectively. Strain AC7 was stored at -80°C in a Luria Bertani 
(LB) broth (Sigma-Aldrich) supplemented with 25% glycerol and grown on LB 
plate for 24 h at 28°C. C. albicans strains were stored at -80°C in Sabouraud 
dextrose broth (Sigma-Aldrich) supplemented with 25% glycerol and grown for 24 
h at 37°C on Sabouraud Dextrose Agar (SDA) plates. 
 
Biosurfactant production and extraction 
For biosurfactant (BS) production, a seed culture was prepared by transferring a 
loop of B. subtilis AC7 strain from a LB agar overnight culture into 20 ml of LB 
broth and incubated at 28°C for 4 h at 140 rpm. Thereafter, 2 ml were inoculated in 
500 ml of the same broth in a 2 l flask and incubated again at 28°C for 24 h at 140 
rpm. The culture broth was then centrifuged at 6000 × g for 20 min and the 
supernatant collected. For BS extraction, the supernatant was acidified to pH 2 with 
6N HCl, stored overnight at 4 °C and extracted three times with ethyl acetate : 
methanol (4 : 1) (Sigma-Aldrich) according to the method described by Rivardo et 
al. [11]. The remaining water in the organic phase was removed by anhydrous 
sodium sulfate. The organic phase was evaporated to dryness under vacuum 
condition and acetone was added to recover raw AC7 BS. Acetone was, then, 
evaporated and AC7 BS collected and weighted. 




Medical-grade silicone elastomeric disks preparation 
In this study medical-grade silicone elastomeric disks (SEDs) (TECNOEXTR 
S.r.l., Italy) with 15 mm in diameter, 1.5 mm in thickness were used for 
experiments in 12-well culture tissue plates. Each silicone disk was cleaned, 
sterilized and conditioned before use according to the method described by 
Busscher et al. [26]. Briefly, disks were submerged in 200 ml of distilled water 
supplemented with 1.4 % (v/v) of RBS 50, sonicated for 5 min at 60 kHz using 
Elma S30H (Elmasonic, VWR International) and rinsed in 1 l of MilliQ water for 
two times. Then, disks were submerged in 20 ml of MeOH (99 %) (Sigma-
Aldrich), rinsed twice, dried under a sterile hood and steam sterilized for 15 min at 
121°C. Before use, each silicone disk was aseptically transferred into 2 ml of Fetal 
Bovine Serum (FBS) (Sigma-Aldrich), incubated at 37°C for 24 h at 140 rpm and 
rinsed with PBS to provide for a serum protein coating simulating blood contact 
during clinical use. 
 
Anti-adhesion and anti-biofilm assays  
Silicone disks were submerged in 2 ml of AC7 BS solution at the concentration of 
2 mg ml
-1
 (AC7 BS test group) or in PBS only (control group) at 37°C for 24 h at 
140 rpm. C. albicans cells were grown for 24 h at 37°C in 25 ml of YNBD at 140 
rpm. After centrifugation and two washings with PBS, the pellet was resuspended 




. Farnesol (Sigma Aldrich) 
was diluted in pure methanol to obtain a 50 mM working stock solution. Farnesol 
was added to the standardized suspension of C. albicans and to the growth medium 
to test a final concentration of 100 µM. Two milliliters of fungal suspension were 
added to each well of a 12-well plate containing silicone disks. After 1.5 h of 
adhesion phase, the disks were transferred in new plates containing 2 ml of YNBD 
and incubated at 37°C with gentle shaking for 24 h. Furthermore, the effect of 
farnesol was also evaluated on preformed biofilms. C. albicans biofilms were 




formed on AC7 BS test group and control group disks (6 disks per group) for 24 h 
at 37°C by using the protocol described above. Following biofilm formation, three 
disks per group were added with farnesol at the final concentration of 100 µM and 
then incubated for additional 24 h at 37°C.  
Assays were carried out in triplicate by means of the viable cell counting method 
(see following paragraph) and experiments were repeated two times. Results were 
expressed as mean log10 CFU/disk . 
 
Viable cell counting  
The effect of AC7 BS, farnesol and AC7 BS + farnesol on C. albicans 40, C. 
albicans 42 and C. albicans IHEM 2894  adhesion and biofilm formation was 
evaluated by the viable cell counting method. After 1.5, 24 and 48 h incubation, 
disks were washed three times with PBS to remove non-adherent cells, inserted 
into 50 ml tubes containing 10 ml PBS and subjected to four cycles of sonication 
(30 s) and stirring (30 s). The disrupted biofilm cells were serially diluted in PBS 
and 1 ml of each dilution was included into melted SDA (Sigma-Aldrich) using the 
pour-plate method. Agar plates were incubated for 24 h at 37°C and colonies were 
then enumerated. Results were expressed as log10 CFU/disk. 
 
Scanning Electron Microscopy analyses 
A second set of samples, equivalent to that realized for the viable cell count, was 
prepared to perform a qualitative and quantitative analysis of C. albicans IHEM 
2894 biofilm formation by scanning electron microscopy (SEM). At the end of 
incubation times, each disk was washed three times in PBS to remove the culture 
medium and the non-adherent cells from the silicone substrate, fixed by immersion 
in aldehydic solution (2.5% glutaraldehyde in 0.1mM phosphate buffer) for 24 h at 
4°C, washed twice in distilled water, dehydrated by immersion in ascending 
alcohol solutions (70%, 90% and 100% ethanol, 10 min each) and dried overnight 




under a laminar flow cabinet. Finally, dried samples were glued to SEM sample 
holder by double bonding carbon tape and gold sputtered. 
SEM analyses were conducted in a XL30 ESEM FEG (Fei-Eindhoven, The 
Netherland) scanning electron microscope at a 10 KV beam voltage. A preliminary 
qualitative investigation of the Candida biofilm was performed at a magnification 
ranging from 100× to 10000×. A representative selection of images at 1000× was 
stored by collecting the secondary electrons signal revealing fine morphological 
details of cells and extracellular matrix.  
For quantitative purposes, two sets of images were also acquired per each sample. 
A first set of nine different fields of view was obtained by collecting the 
backscattered electrons signal at a magnification of 40×, thus guaranteeing the 
observation of a total area of 64 mm
2
 at the silicone disk centre. To distinguish 
between biofilm covered surface and exposed silicone, compositional contrast was 
stressed and images were processed according to a protocol adapted from Bressan 
et al. [27]. Briefly, high resolution digital images (1936×1452 pixels) were 
acquired and then threshold by semi-automated routine implemented in ImageJ 
(NIH, US). The number of dark pixels associated to Candida biofilm and bright 
pixels representing the silicone surface was obtained. Percent area of the silicone 
disk covered by Candida biofilm (BA%) was computed calculating the percent 
ratio of dark pixels over the whole pixels number of the image. 
 
Confocal Laser Scanning Microscopy analyses 
A third equivalent set of samples was also realized for the analysis of C. albicans 
IHEM 2894 biofilm by Confocal Laser Scanning Microscopy (CLSM). After 
incubation, each disk was washed three times in PBS to remove the culture 
medium and non-adherent cells from the silicone substrate and incubated for 30 
min at 37°C in 2 ml of staining solution composed by 2 µl of 10 mM FUN-1 
solution (Life Technologies) and 10 µl of Concavalin A (CON-A, Life 




Technologies) 5 mg ml
-1
 solution in PBS. Observations were performed with an 
inverted confocal microscope (Nikon A1, Nikon Corporation, Japan) in wet 
conditions with the sample positioned upside down, to avoid the opaque silicone 
disk interference. Samples were scanned using 488 nm and 525 nm excitation 
wavelengths and collecting emissions at 525/25 nm and 650/100 nm respectively. 
 
Statistical analysis of data 
Statistical analysis and graphs were elaborated by means of the statistical program 
R, 3.1.2. (R Development Core Team, http//www.R-project.org).  
Two-way ANOVA followed by Tukey’s HSD test was performed to investigate the 
effect of AC7 BS alone, farnesol alone or AC7 BS + farnesol on the three C. 
albicans stains adhesion and biofilm formation in assays carried out by means of 
the viable cell counting method. The R package dupiR was used to estimate log10 
CFU/disk from colony counts [28]. Results were considered to be statistically 
significant when P<0.05.  
 
Results and discussion 
 
Anti-biofilm activity of AC7 BS and farnesol 
The activity of AC7 BS (2 mg ml
-1
) and farnesol (100 µM) was evaluated on 
different stages of C. albicans biofilm development on medical-grade silicone, at 
physiological conditions (37 °C), in the presence of a proteinaceous solution, i.e. 
fetal bovine serum, to mimic blood contact during clinical use in internal body 
conditions. Figure 1 show the activity of farnesol alone, AC7 alone and of the 
combination of AC7 BS with farnesol against C. albicans biofilm formation on 
silicone disks in pre-coating assays at different incubation times. Panels show that 
fungal adhesion and biofilm formation on AC7 BS, farnesol and AC7 BS + 




farnesol treated disks is lower  than on untreated disks at all incubation times. 
According to two-way ANOVA Candida albicans biofilm development is 




Table 1 summarizes the results obtained for the three C. albicans strains expressed 
as means log10 CFU/disk and the 95% confidence intervals.  
 
Table 1. Mean C. albicans 40, C. albicans 42 and C. albicans IHEM 2894 
concentrations, expressed as log10 CFU/disk, recovered on silicone disks and 95% 
confidence intervals, in anti-adhesion (1.5 h) and anti-biofilm (24 and 48 h) assays. 
 
The number of adherent cells on control disks after 1.5 h was 5.63 log10 CFU/disk 
for C. albicans 40, 5.63 log10 CFU/disk for strain 42 and 5.61 log10 CFU/disk for 
strain IHEM 2894,  it increased to 7.72 log10 CFU/disk for C. albicans 40, 7.64 
log10 CFU/disk for strain 42 and 7.77 log10 CFU/disk for strain IHEM 2894 after 24 
h and to 8.13 log10 CFU/disk for C. albicans 40, 7.98 log10 CFU/disk for strain 42 
and 8.10 log10 CFU/disk for strain IHEM 2894 after 48 h. 
The number of adherent cells on disks treated with farnesol after 1.5 h was 5.40 
log10 CFU/disk for C. albicans 40, 5.41 log10 CFU/disk for strain 42 and 5.34 log10 
CFU/disk for strain IHEM 2894, it increased to 7.10 log10 CFU/disk for C. albicans 
40, 7.05 log10 CFU/disk for strain 42 and 7.06 log10 CFU/disk for strain IHEM 
2894 after 24 h and to 8.03 log10 CFU/disk for C. albicans 40, 7.89 log10 CFU/disk 
for strain 42 and 7.98 log10 CFU/disk for strain IHEM 2894 after 48 h. 
Time 
(h) 
Strain Control  Farnesol   AC7 BS  AC7 BS + farnesol   
















1.5 C. albicans 40 5.63 [5.57, 5.68]      5.40 [5.38, 5.42]     5.41 [5.39, 5.43]      5.04  [5.01, 5.07      
 C. albicans 42 5.63  [5.58, 5.68]      5.41 [5.39, 5.44]    5.42 [5.40, 5.44]      5.08  [5.05, 5.11]      
 
C. albicans  
IHEM 2894 
5.61 [5.56, 5.67]    5.34 [5.32, 5.37]    5.37 [5.35, 5.40]   4.99 [4.96, 5.03]    
24 C. albicans 40 7.72 [7.67, 7.76]      7.10 [7.07, 7.13]   7.55 [7.49, 7.61]      6.93  [6.89, 6.97]      
 C. albicans 42 7.64 [7.58, 7.69]      7.05 [7.02, 7.09]      7.48 [7.42, 7.55]   6.84  [6.80, 6.88]   
 
C. albicans  
IHEM 2894 
7.77 [7.72, 7.81]  7.06 [7.03, 7.10]    7.59 [7.53, 7.64]    6.63  [6.57, 6.68] 
48 C. albicans 40 8.13 [8.10, 8.16] 8.03 [8.00, 8.07]   8.01 [7.97, 8.04]      7.83 [7.78, 7.87] 
 C. albicans 42 7.98  [7.95, 8.02]      7.89 [7.85, 7.93]     7.87 [7.83, 7.91]      7.71  [7.66, 7.76]   
 
C. albicans  
IHEM 2894 
8.10 [8.07, 8.13]    7.98 [7.94, 8.02]    7.95 [7.91, 7.99]    7.70  [7.66, 7.75]    




The number of adherent cells on AC7BS pre-coated disks after 1.5 h was 5.41 log10 
CFU/disk for C. albicans 40, 5.42 log10 CFU/disk for strain 42 and 5.37 log10 
CFU/disk for strain IHEM 2894, it increased to 7.55 log10 CFU/disk for C. albicans 
40, 7.48 log10 CFU/disk for strain 42 and 7.59 log10 CFU/disk for strain IHEM 
2894 after 24 h and to 8.01 log10 CFU/disk for C. albicans 40, 7.87 log10 CFU/disk 
for strain 42 and 7.95 log10 CFU/disk for strain IHEM 2894 after 48 h. 
The number of adherent cells on AC7 BS pre-coated disks treated with farnesol 
after 1.5 h was 5.04 log10 CFU/disk for C. albicans 40, 5.08 log10 CFU/disk for 
strain 42 and 4.99 log10 CFU/disk for strain IHEM 2894, it increased to  6.93 log10 
CFU/disk for C. albicans 40, 6.84 log10 CFU/disk for strain 42 and 6.63 log10 
CFU/disk for strain IHEM 2894 after 24 h and to 7.83 log10 CFU/disk for C. 
albicans 40, 7.71 log10 CFU/disk for strain 42 and 7.70 log10 CFU/disk for strain 
IHEM 2894 after 48 h. 
 
Figure 1. Inhibition of C. albicans adhesion and biofilm formation on silicone 
elastomeric disks, evaluated at 1.5, 24 and 48 h. c: control; b: AC7 BS, f: farnesol; 
fb: AC7BS + farnesol. 
 
Mean percentages of reduction are reported in Table 2. AC7 BS significantly 
reduced C. albicans strains adhesion in a range between 38.5% and 42% and 




biofilm formation in a range between 30.3% and 34.8% respectively. Furthermore, 
it reduced pre-formed biofilms in a range between 22.9% and 29.1%.  
Farnesol significantly reduced C. albicans strains adhesion and biofilm formation 
in respect to control, showing a reduction of viable cell counts in treated samples 
ranging from 39% to 46.2% after 1.5 h and from 74.1% to 80.4% after 24h, 
respectively. Furthermore, farnesol reduced pre-formed biofilms in a range 
between 19.6% and 23.8%.  
AC7 BS in combination with farnesol significantly reduced the adhesion of the 
three C. albicans strains in a range between 72.1% and 75.9% and biofilm 
formation in a range between 83.8% and 92.9%, respectively. Furthermore, the two 
molecules together reduced pre-formed biofilms in a range between 46.6% and 
59.8%. 
In general, AC7 BS treatment resulted in a significant reduction of the total 
adherent cells and biofilm biomass compared to controls for all the three C. 
albicans strains, as evaluated by the viable cell counting method. The highest 
performance of AC7 BS was observed during C. albicans adhesion phase 
(P<0.001), whereas during the biofilm formation phase the inhibition was lower but 
still significant (P<0.05, at least). Previous results obtained in the Laboratory of 
Microbiology revealed that AC7 BS has no antifungal activity at 2 mg ml
-1 
against 
planktonic and sessile C. albicans cells, suggesting that AC7 BS inhibited pathogen  
 
Table 2. Percentages of inhibition of C. albicans 40, C. albicans 42 and C. 
albicans IHEM 2894 adhesion and biofilm formation in respect to untreated 
controls. 
 
Strain 1.5 h 24 h 48 h  
 
Farnesol AC7 BS 
AC7 BS + 
 farnesol  
Farnesol AC7 BS 
AC7 BS +  
farnesol 
Farnesol AC7 BS 
AC7 BS + 
farnesol 
C.albicans 40  40.9  39.3 74.0 75.9 31.7 83.8 19.6  23.9 50.9 
C.albicans 42 39.0  38.5 72.1 74.1  30.3 83.9 20.5  22.9 46.6 
C.albicans IHEM 
2894 46.2 
42.0 75.9 80.4  34.8 92.9 23.8  29.1 59.8 




adhesion without affecting cell growth.  
BS AC7 was attached to the silicone elastomeric disks by a physical absortion 
strategy, in a non-covalent manner. It is therefore possible that biosurfactant film 
might have been gradually removed from the surfaces during the transferring step 
involved in esperimental setting, leading to a loss of activity.  
Recently, Pinto et al. [29] have modified a Poly(dimethyl siloxane) surface by 
argon plasma treatment followed by the coating with different biosurfactants 
isolated from probiotic strains, to evaluate how these compounds affect the PDMS 
surface properties. Tested materials had no toxicity and were found to be non-
hemolytic, indicating that the proposed approach may open new possibilities for 
the application of these surfaces in the biomedical field.  
Starting from these encouraging results, AC7 BS will be covalently bound to 
silicone by physical or chemical surface modification to improve and prolong its 
anti-adhesive and anti-biofilm properties. 
Farnesol showed the highest inhibitory effect at 24 h, during the biofilm formation 
phase (P<0.001). A lower effect was observed when farnesol was evaluated during 
the adhesion phase (P<0.001) or when it was added to pre-formed biofilms 
(P<0.01, at least). Similar results were obtained by Jabra-Rizk et al. and Ramage et 
al. [6,30]. In both studies, the addition of farnesol at the concentration of 100-300 
µM to the initial fungal suspension resulted in a higher reduction of biofilm 
formation whereas a lower effect, although still significant, was revealed on pre-
formed biofilm. The reduced effect of farnesol on pre-formed biofilm could be 
related to the ability of this molecule to inhibit mycelial development in newly 
produced cells without affecting the already formed biofilm [30]. Ramage et al. [6] 
noted that the initial adhesion phase, prior to the addition of farnesol, was 
important in terms of the ability of farnesol to inhibit biofilm formation. Adherent 
cell populations that began to germinate naturally were not inhibited by a 
subsequent addition of farnesol.  




The effect of AC7 BS and farnesol was found to be similar during the adhesion 
phase and on pre-formed biofilm (P>0.05). On the contrary, at 24 h the two 
compounds were found to perform differently (P<0.001).  
To our knowledge, it is the first time that the possible synergistic effect of farnesol 
and biosurfactant is studied. 
AC7 BS in combination with farnesol significantly reduced C. albicans adhesion 
(P<0.001) and biofilm formation (P<0.001). Furthermore, the two compounds 
together significantly reduced pre-formed biofilm (P<0.001). In addition, the effect 
obtained by the combination of the two compounds differed significantly from 
those observed with AC7 BS and farnesol alone.  
 
SEM and CLSM analyses 
Qualitative analysis of C. albicans IHEM 2894 biofilm microstructure on high 
magnification SEM images and CLSM images evidenced a less compact structure 
of the biofilm between samples treated with AC7BS alone, farnesol alone, AC7BS 
+ farnesol and controls. From a comparative evaluation of the fluorescence from 
FUN-1 (addressing membrane integrity and metabolic capability) and Con-A 
(addressing cell membrane) it is possible to assess that, for all the samples, the 
biofilm is characterized by a high vitality 
Moreover, a complex three dimensional structure with long hyphae arranged in a 
multilayered network was found in controls at 24 and 48h of incubation. 
Differently, treated samples did not developed a thick hyphal network at the tested 
conditions. No phenotipical differences were found between microorganisms 
growth on test or control samples showing, in both cases, ovoid spherical 
blastoconidia with polarly or randomly located budding and true hyphae formation. 
Difference in the amount of extracellular material was also documented. 







Figure 2. Scanning electron micrographs of silicone elastomeric disks after C. 
albicans IHEM 2894 adhesion phase (1.5 h), biofilm formation (24 h) and pre-
formed biofilm (48 h). Original magnification 1000×. 
 
The quantification of the silicone disk area covered by C. albicans IHEM 2894 
biofilm (BA%) on SEDs showed a similar trend. Differences in BA% between 
samples treated with AC7BS alone, farnesol alone and AC7BS + farnesol and 
controls were observed (Table 3). After 1.5h of incubation, 24% of the control 
disks surface was covered by C. albicans cells whereas, only 11.2% of the farnesol 
treated disks, 11.5% of the BS treated disks, and 8.6%. of AC7 BS +  farnesol 
treated disks. During the biofilm formation phase, control disks were almost totally 
covered (97%) by C. albicans IHEM 2894 biofilm  both at 24 and and at 48h, 




whereas disks treated with AC7BS showed a BA% of 67% and 39%, disks treated 
with farnesol of 13% and 68%, disks treated with AC7 BS + farnesol of 7% and 
25%, respectively at 24 and 48h.  
 
Table 3. Percentages of C. albicans IHEM 2894 biofilm covered surface evaluated 
by SEM and ImageJ (NIH, U.S.) on silicone elastomeric disks. 
 
A preliminary evaluation of the film thickness, educible from the multi-stack 
images acquired from confocal microscope, evidences that after 24 hours the 
AC7BS + farnesol treated samples are capable of a significant reduction in the 
biofilm thickness (Table 4). Both farnesol and AC7BS alone have a similar 
behavior with respect to the control sample, while they seem to express a detectable 
capacity in controlling the biofilm thickness only after 48 hours. 
 
 Biofilm thickness (µm) 
 Time (h) 
Sample 24 48 
 Mean IE* Mean IE* 
Control 56   2 58  2 
Farnesol 56   2 46  2 
AC7BS 54   2 41  2 
AC7BS + farnesol   36   2 38   2 
 




Biofilm covered surface (%)  
Control Farnesol AC7 BS AC7 BS + farnesol 
 Mean SD* Mean SD* Mean SD* Mean SD* 
1.5 24 4 11.2 2 11.5 3 8.6 2 
24 97 1 13 17 67 10 7 3 
48 97 1 68 21 39 36 25 4 





Figure 3. Confocal laser scanning micrographs of silicone elastomeric disks after 
C. albicans IHEM 2894 adhesion phase (1.5 h), biofilm formation (24 h) and pre-
formed biofilm (48 h). Scale bar is 100 µm. 
 
 





Nowadays, the urgent need for new antimicrobial compounds induced by the newly 
emerged pathogens and increased resistance shown by conventional others remains 
a major breakthrough in the clinical practice and preventive medicine [9,31]. In this 
contest, biosurfactants are recognized as compounds endowed with potent 
biological activities and some of them have been already described as alternatives 
to synthetic medicines and antimicrobial agents [16,32,33]. Lipopeptide 
biosurfactant AC7 is able to reduce significantly C. albicans cell adhesion and 
biofilm formation on medical grade silicone disks. Furthermore, it does not inhibit 
C. albicans  planktonic cells and biofilm, thus indicating an anti-adhesive but not 
antifungal activity. In addition, when lipopeptide biosurfactant AC7 is used 
together with farnesol against C. albicans adhesion, growing biofilm or pre-formed 
biofilm, a synergistic effect is observed. These results suggest that AC7BS, thanks 
to its ability to change the surface characteristics, alone or in combination with 
quorum-sensing molecules, can be considered a potential inhibitor of biofilm 
growth on medical insertional materials. 
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Biosurfactants are amphiphilic molecules having hydrophilic and hydrophobic 
moieties that confer them the ability to exhibit surface activities at interfaces [1]. 
Particularly, these molecules reduce surface and interfacial tension at gas-liquid-
solid interfaces forming a molecular interfacial film that affects the properties 
(surface energy and wettability) of the original surface [2]. Biosurfactants present 
numerous and interesting physicochemical and biological features such as 
antibacterial, antifungal and anti-adhesive activities that make them attractive to a 
wide range of potential pharmaceutical and biomedical applications [3]. In 
particular, the ability to destabilize cell membranes by disturbing their integrity and 
permeability and to affect microorganism adhesion by modifying surface 
characteristics are valuable properties for their use in the treatment of infection 
caused by microbial biofilms on medical devices [4,5]. The presence of biofilm 
protects the microorganism from host defenses and reduces significantly its 
susceptibility to antimicrobial agents [6]. Furthermore, the tenancy with which 
microrganisms infect indwelling medical devices necessitates, in almost all the 
cases, their removal [7]. 
Candida species are responsible of an increasing number of these infections, 
especially those involving central and peripheral venous catheters, urinary 
catheters, tracheal tubes, neurosurgical shunts, voice prostheses, dentures and 
intrauterine devices [8]. Candida spp. cause 10% of the overall infections of 
intravenous catheters and cardiac devices prosthetic valves as well as 21% of the 
total cases of urinary catheters infection with a mortality rate of 20-40% [9]. In 
particular, C. albicans represents the fungus most frequently associated with the 
formation of biofilms on a wide variety of medical devices [10-13]. Quorum-
sensing plays an important role in C. albicans biofilm development because it 
regulates all phases of biofilm life cycle. The quorum-sensing molecule farnesol 
inhibits hyphal growth and the expression of necessary morphology-specific genes 




for the yeast-to-mycelium conversion of C. albicans leading to a decrease of 
biofilm size, suggesting a potential use for biofilm restraint [14, 15]. 
Current biofilm preventive strategies are essentially aimed at increasing material 
hydrophilicity [16, 17], thus decreasing microbial adhesion and biofilm formation, 
or at coating medical-device surfaces with antimicrobial agents [18]. Main 
drawbacks of antimicrobial coatings arise from time limited effectiveness due to 
oxidative degradation, development of microorganism resistance and potential 
toxicity towards human cells [19, 20]. From this point of view, it could be useful to 
increase the efficacy of known antibiotics and biocides with alternative strategies 
aimed at decreasing bacterial adhesion and reducing the biofilm populations on 
medical device surfaces. 
My PhD research activity has been mainly focused on the study of two bacterial 
biosurfactants - CV8LAC BS produced by Lactobacillus brevis and AC7 BS 
produced by Bacillus subtilis – and their activity against Candida albicans biofilm 
formation.  
In a previous work, it has been shown that CV8LAC BS decreased the adhesion of 
two biofilm-producer strains of C. albicans derived from culture collections of 
more than 80% in pre-coated polystyrene microtiter plates [21]. On the other hand, 
the use of AC7 BS for the prevention of Candida albicans biofilm formation on 
silicone disks and acrylic resins has been recently reported [22]. Pre-coating with 
this biosurfactant caused a greater reduction in biofilm cell number and viability 
than chlorhexidine. In addition, the biosurfactant concentrations used in the anti-
adhesive assays were found to be significantly less cytotoxic than chlorhexidine in 
both fibroblast and keratinocyte in vitro cell models. 
In this work, a clinically oriented approach was chosen in order to assess whether 
the effects previously obtained were still present when applying wild strains on 
medical grade polymers. To fulfill this aim, we used clinically relevant wild strains 
(C. albicans 40 and 42) isolated respectively from a central venous catheter and a 
urinary catheter, both made of silicone elastomer that is the very same biomaterial 




chosen as substratum for our assays, and a strain isolated from the tongue and 
obtained from a public collection (C. albicans IHEM 2894). 
In order to assess the anti-adhesive and anti-biofilm activity of BS on Candida, a 
number of different complementary methods (fungal biomass staining, viable cell 
counting, microscopic analysis) on multiple strains were used, to deeply address 
and understand the phenomena we were observing. In particular, first a co-
incubation method was used, where biosurfactant solutions were added to 
microbial inocula or media. Secondly, in order to imitate a functional coating 
condition, a pre coating method was used, in which biosurfactant was previously 
adsorbed on the surface of silicone disks. 
In collaboration with Prof. Maurizio Rinaldi - Department of Pharmaceutical 
Sciences, Novara, a deep statistical analysis was carried out with multiple tests 
allowing to confirm the significance of data. Statistical analysis and graphs were 
elaborated by means of the statistical program R (R Development Core Team, 
http//www.R-project.org). One-way or two-way ANOVA were used to compare 
optical densities of C. albicans planktonic cells and pre-formed biofilm at different 
biosurfactant concentrations. Two-way ANOVA followed by Tukey’s HSD test 
was used to evaluate the effect of the two biosurfactants on C. albicans adhesion 
and biofilm formation in co-incubation and pre-coating assays carried out by means 
of CV staining method. Welch Two Sample t-test and two-way ANOVA followed 
by Tukey’s HSD test were performed to investigate the effect of the two 
biosurfactants on C. albicans adhesion and biofilm formation in co-incubation and 
pre-coating assays carried out by means of the viable cell counting method. R 
package Dupi R was used to estimate log10 CFU/disk from colony counts. Chi-
square test with Yates’ continuity correction was used to compare proportions of 
hyphae and blastospores at the different time points. 
Results demonstrated that both biosurfactants were able to inhibit significantly the 
adhesion and, to a lower extent, to slow biofilm formation of different C. albicans 
strains on silicone elastomer, at physiological conditions. 




Co-incubation of C. albicans 40 with CV8LAC BS induced a significant reduction 
of biofilm formation in respect to controls by a log10 factor ~1 (i.e. about 90%) at 
all incubation times (24, 48, 72 h). In addition, in pre-coating assays, fungal 
adhesion was significantly reduced by 62% at 1.5 h and biofilm formation was 
inhibited by 53%, 50% and 44% after 24, 48 and 72 h of incubation, respectively. 
In co-incubation assays, AC7 BS induced a significant reduction of fungal biomass 
of the three strains by an average of 68% at 1.5 h, and by an average of 56 % at 24 
h in respect to controls. In pre-coating assays, a significant reduction in fungal 
biomass by an average of 61% at 1.5 h, and of 49% at 24 h was detected. Using the 
viable cell counting method, the adhesion of the three C. albicans stains was 
significantly reduced by an average of 60% at 1.5 h and biofilm formation was 
significantly inhibited by an average of 47% after 24 h of incubation. 
The anti-adhesion and anti-biofilm activity displayed by CV8LAC and AC7 
biosurfactants cannot be attributed to an antifungal action, as the growth of 
Candida planktonic and sessile cells was not inhibited by both biosurfactants. It 
can be supposed that CV8LAC and AC7 biosurfactants influence bacterial-surface 
interactions thanks to their ability to change surface tension and bacterial cell-wall 
charge, affecting both cell-to-cell and cell-to-surface interactions and, as a result, 
the surface is made less supportive for bacterial adhesion.  
The decreased activity of CV8LAC BS and AC7 BS on biofilm formation in pre-
coating assays compared to co-incubation assays may be due to the strategy chosen 
to coat the silicone surface, as this was simply done by physical adsorption. The 
biosurfactant molecules are attached to the surface by weak bounds (hydrogen 
bounds, Van der Walls forces) and not by covalent bounds. Hence, during the 
washing steps involved in the experimental setting, the biosurfactant might have 
been gradually removed from silicone, leading to activity loss. 
In collaboration with the research groups directed by Prof. Giandomenico Nollo at 
the Department of Industrial Engineering of University of Trento and by Prof. Iole 
Caola at the Section of Electron Microscopy of Department of Medicine 




Laboratory, Azienda Provinciale per i Servizi Sanitari di Trento, SEM and CLSM 
analyses were conducted on C. albicans 40 and C. albicans IHEM 2894 adherent 
cells and biofilms. SEM microscopic and CLSM observation supported cultural 
data of the biofilm on silicone disks. During the adhesion phase, the number of 
attached cells on silicone surfaces was significantly reduced on biosurfactant 
treated disks. A complex three-dimensional structure with long hyphae arranged in 
a multilayered network was evidenced in controls of mature biofilms. On the 
contrary, a less compact structure of the biofilm was found in treated samples. No 
morphological differences were found between microorganisms growth on test or 
control samples showing, in both cases, ovoid spherical blastoconidia with polarly 
or randomly located budding and true hyphae formation. Difference in the amount 
of extracellular material was also documented. Furthermore, the analysis of 
quantitative SEM data on the percentage of polymer surface covered by biofilm 
showed lower values in treated samples in respect to controls. CV8LAC BS pre-
coated silicone disks were characterized by a percent area of the silicone disk 
covered by Candida biofilm (BA%) reduction of 57% after 1.5 h and of 26%, 11% 
and 4.5% after 24h, 48h and 72h respectively, when compared to control disks. On 
the other hand, the pre-treatment of silicone disks with AC7 BS led to a BA% 
reduction of 52% after 1.5 h and of 31%, and 60% after 24 h and 48 h respectively. 
Finally, when AC7 BS was used together with farnesol, a synergistic effect was 
observed. In particular, AC7BS in combination with farnesol 100 µM significantly 
reduced C. albicans adhesion up to 74% at 1.5 h and biofilm formation up to 93% 
and 60% at 24 h and 48 h, respectively. Concerning BA% reduction, the combined 
use of AC7 BS and farnesol led to a decrease of 64% after 1.5 h and of 92%, and 
74% after 24 h and 48 h respectively, when compared to control disks.  
These findings suggest a potential use of biosurfactants in combined therapies (e.g. 
combination with antifungal drugs). Preliminary results obtained in the Laboratory 
of Microbiology revealed a synergistic effect by combining the biosurfactant with 
Amphotericin B.C. albicans 40 and 42 represented, in this study, very good models 




to evaluate the anti-adhesive and anti-biofilm activity of CV8LAC and AC7 BS on 
silicone elastomer. This consideration also brought us to deposit the two strains in 
the DSMZ public collection. Nevertheless, a larger number of C. albicans strains is 
expected to be tested to exhaustively verify anti-adhesion properties of the two 
biosurfactans in future.  
Moreover, the activity of both biosurfactants will be evaluated on clinically 
relevant biofilm-producer bacterial strains. Recently, preliminary results obtained 
in the Laboratory of Microbiology have shown that AC7 BS is able to reduce 
biofilm formation of P aeruginosa by 82%, of S. epidermidis ATCC35984 by 74% 
and of E. coli CFT073 by 72%, suggesting promising potentialities against 
bacterial biofilms. 
AC7 BS was fully characterized. The LC/ESI-MS analysis, carried out by Prof. 
Gianna Allegrone - Department of Pharmaceutical Sciences - Novara, revealed the 
presence of the homologues of two lipopeptide families, principally surfactin 
family and a lower percentage of fengycin family. Chemical characterization of 
CV8LAC BS will be carried out in the near future. According to a preliminary TLC 
analysis, two substances were detected at 254 nm UV light and other two 
substances, at minor retention factor, were visualized by spraying a specific reagent 
to detect sugars.  
Finally, physical or chemical surface modification will be tested in the future to 
bind the biosurfactants more efficiently to the silicone surface in order to improve 
and prolong anti-biofilm properties. Considering the wide selection of methods 
nowadays available for bonding biomolecules onto medical grade polymers, the 
anti-adhesive properties of the CV8LAC and AC7 BS deserve a promising role as 
anti-adhesive products to effectively limit colonization and prevent C. albicans 
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